Publications

Michael Pollak. Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2024 Jan 4;390(1):90.

Devalingam Mahalingam, Salih Hanni, Anthony V Serritella, Christos Fountzilas, Joel Michalek, Brian Hernandez, John Sarantopoulos, Paromitta Datta, Ofelia Romero, Sureshkumar Mulampurath Achutan Pillai, John Kuhn, Michael Pollak, Ian M Thompson. Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer. Oncotarget. 2023 Jun 19;14:622-636. 

Hannah R. Bridges, James N. Blaza, Zhan Yin, Injae Chung, Michael N. Pollak, Judy Hirst. Structural Basis of Mammalian Respiratory Complex I Inhibition by Medicinal Biguanides. Science. 2022 Jan 27; 379 (6630), 351–357.

Maxime Parisotto, Nhung Vuong-Robillard, Paloma Kalegari, Thulaj Meharwade, Loick Joumier, Sebastian Igelmann, Véronique Bourdeau, Marie-Camille Rowell, Michael Pollak, Mohan Malleshaiah, Andréea Schmitzer, Gerardo Ferbeyre. The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells. Cancers (Basel). 2022 Nov 14;14(22):5597. 

Kenneth C Anderson, Lewis C Cantley, Riccardo Dalla-Favera, Chi Van Dang, Luis A Diaz, Raymond N DuBois, Keith T Flaherty, Philip D Greenberg, Massimo Loda, Elaine R Mardis, Elizabeth A Platz, Michael N Pollak, Robert D Schreiber, Lillian L Siu, Beverly A Teicher. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission.

Cancer Discov. 2022 Nov 2;12(11):2475-2481.

Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):1995-2001.

Cancer Immunol Res. 2022 Nov 2;10(11):1282-1288.

Blood Cancer Discov. 2022 Nov 2;3(6):469-475.

Cancer Res. 2022 Nov 2;82(21):3861-3867.

Clin Cancer Res. 2022 Nov 1;28(21):4593-4599.

Cancer Prev Res (Phila). 2022 Nov 1;15(11):705-712.

download

download

download

download

download

download

download

Raymond N DuBois, Michael N Pollak. Introducing Cancer Center Director Perspectives on Prevention. Cancer Prev Res (Phila). 2022 Nov 1;15(11):713-714. 

Chaoran Ma, Ye Wang, Kathryn M Wilson, Lorelei A Mucci, Meir J Stampfer, Michael Pollak, Kathryn L Penney. Circulating Insulin-Like Growth Factor 1-Related Biomarkers and Risk of Lethal Prostate Cancer. JNCI Cancer Spectr. 2021 Dec 15;6(1):pkab091. 

Altaf Mohammed, Roderick H. Dashwood, Sally Dickinson, Mary L. Disis, Elizabeth M. Jaffee, Bryon D. Johnson, Samir N. Khleif, Michael N. Pollak, Jeffrey Schlom, Robert H. Shoemaker, Sasha E. Stanton, Georg T. Wondrak, Ming You, Hao Zhu, Mark Steven Miller. Translational Advances in Cancer Prevention Agent Development (TACPAD) Virtual Workshop on Immunomodulatory Agents: Report. J Cancer Prev 26(4):309-317, December 30, 2021.

Cindy H Chau, Cathee Till, Douglas K Price, Phyllis J Goodman, Marian L Neuhouser, Michael N Pollak, Ian M Thompson, William D Figg. Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. Endocr Relat Cancer. 2022 Jan 20;29(2):99-109. 

Nahid Yazdanpanah, Mojgan Yazdanpanah, Ye Wang, Vincenzo Forgetta, Michael Pollak, Constantin Polychronakos, J Brent Richards, Despoina Manousaki. Clinically Relevant Circulating Protein Biomarkers for Type 1 Diabetes: Evidence From a Two-Sample Mendelian Randomization Study. Diabetes Care. 2022 Jan 1;45(1):169-177.

Frank A Sinicrope, Qian Shi, Thomas C Smyrk, Richard M Goldberg, Steven J Cohen, Sharlene Gill, Morton S Kahlenberg, Suresh Nair, Anthony F Shield, Balkrishna N Jahagirdar, Sawyer B Jacobson, Nathan R Foster, Michael N Pollak, Steven R Alberts. Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. JNCI Cancer Spectr. 2021 Jul 23;5(5):pkab070.

Stephanie P Totten, Young Kyuen Im, Eduardo Cepeda Cañedo, Ouafa Najyb, Alice Nguyen, Steven Hébert, Ryuhjin Ahn, Kyle Lewis, Benjamin Lebeau, Rachel La Selva, Valérie Sabourin, Constanza Martínez, Paul Savage, Hellen Kuasne, Daina Avizonis, Nancy Santos Martínez, Catherine Chabot, Adriana Aguilar-Mahecha, Marie-Line Goulet, Matthew Dankner, Michael Witcher, Kevin Petrecca, Mark Basik, Michael Pollak, Ivan Topisirovic, Rongtuan Lin, Peter M Siegel, Claudia L Kleinman, Morag Park, Julie St-Pierre, Josie Ursini-Siegel. STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer. Nat Commun. 2021 Jun 3;12(1):3299.

*David Papadopoli, Michael Pollak, Ivan Topisirovic. The role of GSK3 in metabolic pathway perturbations in cancer. Biochim Biophys Acta Mol Cell Res. 2021 Jul;1868(8):119059. 

Neil M Iyengar, Xi Kathy Zhou, Hillary Mendieta, Dilip D Giri, Omar El-Hely, Lisle Winston, Domenick J Falcone, Hanhan Wang, Lingsong Meng, Jonathan Landa, Michael Pollak, Laurie Kirstein, Monica Morrow, Andrew J Dannenberg. Effects of Adiposity and Exercise on Breast Tissue and Systemic Metabo-Inflammatory Factors in Women at High Risk or Diagnosed with Breast Cancer. Cancer Prev Res (Phila). 2021 May;14(5):541-550.

Brown JC, Zhang S, Ligibel J, et al. Effect of Exercise or Metformin on Biomarkers of Inflammation in Breast and Colorectal Cancer: A Randomized Trial. Cancer Prev Res (Phila). 2020 Aug 28. Epub ahead of print. 

Molenaar RJ, van Hattum JW, Brummelhuis IS, Oddens JR, Savci-Heijink CD, Boevé ER, van der Meer SA, Witjes JF, Pollak MN, de Reijke TM, Wilmink JW. Study protocol of a phase II clinical trial of oral metformin for the intravesical treatment of non-muscle invasive bladder cancer. BMC Cancer. 2019 Nov 21; 19(1):1133.

Gui Y, Aguilar-Mahecha A, Krzemien U, Hosein A, Buchanan M, Lafleur J, Pollak MN, Ferrario C, Basik M. Metastatic breast carcinoma-associated fibroblasts have enhanced pro-tumorigenic properties related to increased IGF2 expression. Clin Cancer Res. Dec 1;25(23):7229-7242. 2019.

DuBois RN, Pollak MN. Cancer Prevention: A Message from the New Editors-in-Chief. Cancer Prev Res (Phila). 2019 Jan;12(1):1-2.

Lord SR, Cheng WC, Liu D, Gaude E, Haider S, Metcalf T, Patel N, Teoh EJ, Gleeson F, Bradley K, Wigfield S, Zois C, McGowan DR, Ah-See ML, Thompson AM, Sharma A, Bidaut L, Pollak M, Roy PG, Karpe F, James T, English R, Adams RF, Campo L, Ayers L, Snell C, Roxanis I, Frezza C, Fenwick JD, Buffa FM, Harris AL. Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer. Cell Metab 28(5):679-688, 2018.

Uchenunu O*, Pollak M, Topisirovic I, Hulea L. Oncogenic kinases and perturbations in protein synthesis machinery and energetics in neoplasia. J Mol Endocrinol 1;62(2):R83-R103, 2019. 

Tognon CE, Rafn B, Cetinbas NM, Kamura T, Trigo G, Rotblat B, Okumura F, Matsumoto M, Chow C, Davare M, Pollak M, Mayor T, Sorensen PH. Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation. J Biol Chem 293(32):12502-12515, 2018.  

download

Im YK, Najyb O, Gravel SP, McGuirk S, Ahn R, Avizonis D, Chénard V, Sabourin V, Hudson J, Pawson T, Topisirovic I, Pollak MN, St-Pierre J, Ursini-Siegel J. Interplay between ShcA signaling and PGC-1α triggers targetable metabolic vulnerabilities in breast cancer. Cancer Res 78(17):4826-4838, 2018.

download

Wang Y, Nasiri AR, Damsky WE, Perry CJ, Zhang X-M, Rabin-Court A, Pollak MN, Shulman GI, RJ Perry. Uncoupling hepatic oxidative phosphorylation reduces tumor growth in two murine models of colon cancer. Cell Reports, 2018. In press.

download

Kulkarni AS, Brutsaert EF, Anghel V, Zhang K, Bloomgarden N, Pollak M, Mar JC, Hawkins M, Crandall JP, Barzilai N. Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell 17(2), 2018.

Oh H, Pfeiffer RM, Falk RT, Horne HN, Xiang J, Pollak M, Brinton LA, Storniolo AMV, Sherman ME, Gierach GL, Figueroa JD. Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank. Int J Cancer 143(3):496-507, 2018.

Aneke-Nash CS, Xue X, Qi Q, Biggs ML, Cappola A, Kuller L, Pollak M, Psaty BM, Siscovick D, Mukamal K, Strickler HD, Kaplan RC. The Association between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study. J Clin Endocrinol Metab 102(12):4541-4547, 2017.

download

Abrahami D, Yin H, Yu OHY, Pollak MN, Azoulay L. Incretin-based drugs and the incidence of colorectal cancer in patients with type 2 diabetes. Epidemiology 29(2):246-253, 2017.

download

Alemán JO, Iyengar NM, Walker JM, Milne GL, Da Rosa JC, Liang Y, Giri DD, Zhou XK, Pollak MN, Hudis CA, Breslow JL, Holt PR, Dannenberg AJ. Effects of Rapid Weight Loss on Systemic and Adipose Tissue Inflammation and Metabolism in Obese Postmenopausal Women. J Endocr Soc 1(6):625-637, 2017. 

download

Farland LV, Mu F, Eliassen AH, Hankinson SE, Tworoger SS, Barbieri RL, Dowsett M, Pollak MN, Missmer SA. Menstrual cycle characteristics and steroid hormone, prolactin, and growth factor levels in premenopausal women. Cancer Causes Control 28(12):1441-1452, 2017. 

download

Aneke-Nash CS, Xue X, Qi Q, Biggs ML, Cappola A, Kuller L, Pollak M, Psaty BM, Siscovick D, Mukamal K, Strickler HD, Kaplan RC. The Association between IGF-I and IGFBP-3 and Incident Diabetes in an Older Population of Men and Women in the Cardiovascular Health Study. J Clin Endocrinol Metab 102(12):4541-4547, 2017. 

download

Sanders JL, Guo W, O'Meara ES, Kaplan RC, Pollak MN, Bartz TM, Newman AB, Fried LP, Cappola AR. Trajectories of IGF-I Predict Mortality in Older Adults: The Cardiovascular Health Study. J Gerontol A Biol Sci Med Sci 73(7):953-959, 2017. 

download

Wu JW, Azoulay L, Majdan A, Boivin JF, Pollak M, Suissa S. Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. J Clin Oncol 35(32):3647-3653, 2017. 

download

Wang PY, Li J, Walcott FL, Kang JG, Starost MF, Talagala SL, Zhuang J, Park JH, Huffstutler RD, Bryla CM, Mai PL, Pollak M, Annunziata CM, Savage SA, Fojo AT, Hwang PM. Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome. J Clin Invest 127(1):132-136, 2017. 

download

Nogueira LM, Newton CC, Pollak MN, Silverman DT, Albanes D, Männistö S, Weinstein SJ, Jacobs EJ, Stolzenberg-Solomon RZ. Serum C-peptide, total and high molecular weight adiponectin, and pancreatic cancer: Do associations differ by smoking? Cancer Epidemiol Biomarkers Prev26(6):914-922, 2017.

download

Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y. Metabolic heterogeneity signature of primary treatment-naïve prostate cancer. Oncotarget 8(16): 25928-25941, 2017.

download

Pollak MN. Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis. Nat Rev Clin Oncol 14(5): 268, 2017. 

download

Miles FL, Goodman PJ, Tangen C, Torkko KC, Schenk JM, Song X, Pollak M, Thompson IM, Neuhouser ML. Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients 9(4), 2017. 

download

Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VH, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials. Ann Oncol28(7):1560-1568, 2017.

download

Brown KA, Iyengar NM, Zhou XK, Gucalp A, Subbaramaiah K, Wang H, Giri DD, Morrow M, Falcone DJ, Wendel NK, Winston LA, Pollak M, Dierickx A, Hudis CA, Dannenberg AJ. Menopause is a determinant of breast aromatase expression and its associations with BMI, inflammation and systemic markers. J Clin Endocrinol Metab102(5):1692-1701, 2017. 

download

Iyengar NM, Brown KA, Zhou XK, Gucalp A, Subbaramaiah K, Giri DD, Zahid H, Bhardwaj P, Wendel NK, Falcone DJ, Wang H, Williams S, Pollak M, Morrow M, Hudis CA, Dannenberg AJ. Metabolic Obesity, Adipose Inflammation and Elevated Breast Aromatase in Women with Normal Body Mass Index. Cancer Prev Res (Phila) 10(4):235-243, 2017. 

download

Toriola AT, Ziegler M, Li Y, Pollak M, Stolzenberg-Solomon R. Prediagnosis Circulating Insulin-Like Growth Factors and Pancreatic Cancer Survival. Ann Surg Oncol (11):3212-3219, 2017.  

download

Gucalp A, Iyengar NM, Zhou XK, Giri DD, Falcone DJ, Wang H, Williams S, Krasne MD, Yaghnam I, Kunzel B, Morris PG, Jones LW, Pollak M, Laudone VP, Hudis CA, Scher HI, Scardino PT, Eastham JA, Dannenberg AJ. Periprostatic adipose inflammation is associated with high-grade prostate cancer. Prostate Cancer Prostatic Dis 20(4):418-423, 2017. 

download

Hofmann JN, Mailankody S, Korde N, Wang Y, Tageja N, Costello R, Zingone A, Hultcrantz M, Pollak MN, Purdue MP, Landgren O. Circulating adiponectin levels differ between patients with multiple myeloma and its precursor disease. Obesity (Silver Spring)25(8):1317-1320, 2017.

download

Liao LM, Hofmann JN, Cho E, Pollak MN, Chow WH, Purdue MP. Circulating levels of obesity-related markers and risk of renal cell carcinoma in the PLCO cancer screening trial. Cancer Causes Control 28(7):801-807, 2017.​

download

Sgroi DC, Chapman J-A W, Badovinac-Crnjevic T, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Shepherd LE, Goss PE, Pollak M. Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study. Breast Cancer Research 18:1, 2016. 

download

Aneke-Nash CS, Dominguez-Islas C, Bůžková P, Qi Q, Xue X, Pollak M, Strickler HD, Kaplan RC. Agreement between circulating IGF-I, IGFBP-1 and IGFBP-3 levels measured by current assays versus unavailable assays previously used in epidemiological studies. Growth Horm IGF Res 26: 11-6, 2016.

download

Iyengar NM, Zhou XK, Gucalp A, Morris PG, Howe LR, Giri D, Morrow M, Wang H, Pollak M, Jones LW, Hudis CA, Dannenberg AJ. Systemic Correlates of White Adipose Tissue Inflammation in Early-Stage Breast Cancer. Clin Cancer Res 22: 2283-9, 2016.

download

Liu Z, Yokoyama NN, Blair CA, Li X, Avizonis D, Wu XR, Uchio E, Youssef R, McClelland M, Pollak M, Zi X. High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum. Mol Cancer Ther 15: 430-8, 2016.

download

Hofmann JN, Birmann BM, Teras LR, Pfeiffer RM, Wang Y, Albanes D, Baris D, Colditz GA, De Roos AJ, Giles GG, Hosgood HD, Lan Q, Landgren O, Liao LM, Rothman N, Weinstein SJ, Pollak MN, Neuhouser ML, Purdue MP. Low levels of circulating adiponectin are associated with multiple myeloma risk in overweight and obese individuals. Cancer Res 76: 1935-41, 2016.

download

Travis RC, Appleby PN, Martin RM, Holly JM, Albanes D, Black A, Bueno-de-Mesquita HB, Chan JM, Chen C, Chirlaque MD, Cook MB, Deschasaux M, Donovan JL, Ferrucci L, Galan P, Giles GG, Giovannucci EL, Gunter MJ, Habel LA, Hamdy FC, Helzlsouer KJ, Hercberg S, Hoover RN, Janssen JA, Kaaks R, Kubo T, Le Marchand L, Metter EJ, Mikami K, Morris JK, Neal DE, Neuhouser ML, Ozasa K, Palli D, Platz EA, Pollak MN, Price AJ, Roobol M, Schaefer C, Schenk JM, Severi G, Stampfer MJ, Stattin P, Tamakoshi A, Tangen CM, Touvier M, Wald NJ, Weiss NS, Zeigler RG, Key TJ, Allen NE. A meta-analysis of individual participant data reveals an association between circulating levels of IGF-I and prostate cancer risk. Cancer Res 76: 2288-300, 2016.

download

Horne HN, Sherman ME, Pfeiffer RM, Figueroa JD, Khodr ZG, Falk RT, Pollak M, Patel DA, Palakal MM, Linville L, Papathomas D, Geller B, Vacek PM, Weaver DL, Chicoine R, Shepherd J, Mahmoudzadeh AP, Wang J, Fan B, Malkov S, Herschorn S, Hewitt SM, Brinton LA, Gierach GL. Circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3 and terminal duct lobular unit involution of the breast: a cross-sectional study of women with benign breast disease. Breast Cancer Res 18:24, 2016.

download

Gandin V, Masvidal L, Hulea L, Gravel SP, Cargnello M, McLaughlan S, Cai Y, Balanathan P, Morita M, Rajakumar A, Furic L, Pollak M, Porco JA Jr, St-Pierre J, Pelletier J, Larsson O, Topisirovic I. nanoCAGE reveals 5' UTR features that define specific modes of translation of functionally related MTOR-sensitive mRNAs. Genome Res 26: 636-48, 2016.

download

Chandel NS, Avizonis D, Reczek CR, Weinberg SE, Menz S, Neuhaus R, Christian S, Haegebarth A, Algire C, Pollak M. Are Metformin Doses Used in Murine Cancer Models Clinically Relevant? Cell Metab 12: 569-70, 2016.

download

Lian Y, Yin H, Pollak MN, Carrier S, Platt RW, Suissa S, Azoulay L. Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer. Eur Urol 70: 808-815, 2016.

download

Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN. Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14. Breast Cancer Res Treat 157:101-8, 2016.

download

Hayes BD, Brady L, Pollak MN, Finn S. Exercise and prostate cancer: evidence and proposed mechanisms for disease modification. Cancer Epidemiol Biomarkers 25:1281-8, 2016.

download

Teumer A, Qi Q, Nethander M, Aschard H, Bandinelli S, Beekman M, Berndt SI, Bidlingmaier M, Broer L, CHARGE Longevity Working Group,Cappola A, Ceda GP, Chanock S, Chen MH, Chen TC, Chen YI, Chung J, Del Greco Miglianico F, Eriksson J, Ferrucci L,Friedrich N, Gnewuch C, Goodarzi MO, Grarup N, Guo T, Hammer E, Hayes RB, Hicks AA, Hofman A, Houwing-Duistermaat JJ, Hu F, Hunter DJ, Husemoen LL, Isaacs A, Jacobs KB, Janssen JA, Jansson JO, Jehmlich N, Johnson S, Juul A, Karlsson M,Kilpelainen TO, Kovacs P, Kraft P, Li C, Linneberg A, Liu Y, Loos, Body Composition Genetics Consortium, Lorentzon M, Lu Y, Maggio M, Magi R, Meigs J, Mellström D, Nauck M, Newman AB, Pollak MN, Pramstaller PP, Prokopenko I, Psaty BM, Reincke M, Rimm EB, Rotter JI, Saint Pierre A, Schurmann C, Seshadri S, Sjögren K, Slagboom PE, Strickler HD, Stumvoll M, Suh Y, Sun Q, Zhang C, Svensson J, Tanaka T, Tare A, Tönjes A, Uh HW, van Duijn CM, van Heemst D, Vandenput L, Vasan RS, Völker U, Willems SM, Ohlsson C, Wallaschofski H, Kaplan RC. Genomewide meta-analysis identifies loci associated with IGF-I and IGFBP-3 levels with impact on age-related traits. Aging Cell 15: 811-24, 2016.

download

Yancu D, Blouin MJ, Birman E, Florianova L, Aleynikova O, Zakikhani M, VanderMeulen H, Seidman E, Pollak M. A phenotype of IGFBP-3 knockout mice revealed by dextran sulfate-induced colitis. J Gastroenterol Hepatol 32: 146-153, 2016.

download

Choi J, Lee JH, Koh I, Shim JK, Park J, Jeon JY, Yun M, Kim SH, Yook JI, Kim EH, Chang JH, Kim SH, Huh YM, Lee SJ, Pollak M, Kim P, Kang SG, Cheong JH. Inhibiting stemness and invasive properties of glioblastoma tumorsphere by combined treatment with temozolomide and a newly designed biguanide (HL156A). Oncotarget (40): 65643-65659, 2016.

download

Gusscott S, Jenkins CE, Lam SH, Giambra V, Pollak M, Weng AP. IGF1R Derived PI3K/AKT Signaling Maintains Growth in a Subset of Human T-Cell Acute Lymphoblastic Leukemias. PLoS One 11(8):e0161158, 2016.

download

Klil-Drori AJ, Azoulay L, Pollak MN. Cancer, obesity, diabetes, and antidiabetic drugs: is the fog clearing? Nat Rev Clin Oncol 14: 85-99, 2016.

download

Bhat M, Yanagiya A, Graber T, Razumilava N, Bronk S, Zammit D, Zhao Y, Zakaria C, Metrakos P, Pollak M, Sonenberg N, Gores G, Jaramillo M, Morita M, Alain T. Metformin requires 4E-BPs to induce apoptosis and repress translation of Mcl-1 in hepatocellular carcinoma cells. Oncotarget 8(31):50542-50556, 2017. 

download

Hicks BM, Yin H, Yu OH, Pollak MN, Platt RW, Azoulay L. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink. BMJ 355:i5340, 2016.

download

Babic A, Bao Y, Qian ZR, Yuan C, Giovannucci EL, Aschard H, Kraft P, Amundadottir LT, Stolzenberg-Solomon RZ, Morales-Oyarvide V, Ng K, Stampfer MJ, Ogino S, Buring JE, Sesso HD, Gaziano JM, Rifai N, Pollak MN, Anderson ML, Cochrane BB, Luo J, Manson JE, Fuchs CS, Wolpin B. Pancreatic cancer risks associated with prediagnostic plasma levels of leptin and leptin receptor genetic polymorphisms. Cancer Res 76: 7160-7167, 2016.

download

Murphy N, Falk RT, Messinger DB, Pollak M, Xue X, Lin J, Sgueglia R, Strickler HD, Gaudet MM, Gunter MJ. Influence of Fasting Status and Sample Preparation on Metabolic Biomarker Measurements in Postmenopausal Women. PLoS One 11(12):e0167832, 2016.

download

Kaplan RC, Strizich G, Aneke-Nash C, Dominguez-Islas C, Bůžková P, Strickler H, Rohan T, Pollak M, Kuller L, Kizer JR, Cappola A, Li CI, Psaty BM, Newman A. Insulinlike growth factor binding protein-1 and ghrelin predict health outcomes among older adults: CHS cohort. J Clin Endocrinol Metab 1: 267-278, 2016.

download

Inamura K, Song M, Jung S, Nishihara R, Yamauchi M, Lochhead P, Qian ZR, Kim SA, Mima K, Sukawa Y, Masuda A, Imamura Y, Zhang X, Pollak MN, Mantzoros CS, Harris CC, Giovannucci E, Fuchs CS, Cho E, Chan AT, Wu K, Ogino S. Prediagnosis Plasma Adiponectin in Relation to Colorectal Cancer Risk According to KRAS Mutation Status. J Natl Cancer Inst: in press.

download

Allen DB, Backeljauw P, Bidlingmaier M, Biller B, Boguszewski M, Burman P, Butler G, Chihara K, Christiansen JS, Cianfarani S, Clayton PE, Clemmons D, Cohen P, Darendeliler F, Deal C, Dunger DP, Erfurth EM, Fuqua J, Grimberg A, Haymond M, Higham C, Ho KK, Hoffman AR, Hokken-Koelega AC, Johannsson G, Juul A, Kopchick JJ, Lee P, Pollak M, Radovick S, Robison L, Rosenfeld R, Ross RJ, Savendahl L, Saenger P, Toft Sorensen H, Stochholm K, Strasburger CJ, Swerdlow A, Thorner MO. Growth Hormone Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults. Eur J Endocrinol174; 1-9, 2015. 

download

Chapman JW, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN. Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Res and Treat 153: 353-60, 2015.

download

Azoulay L, Eberg M, Benayoun S, Pollak M. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA Oncol 1: 314-20, 2015.

download

Stolzenberg-Solomon RZ, Newton CC, Silverman DT, Pollak M, Nogueira LM, Weinstein SJ, Albanes D, Männistö S, Jacobs EJ. Circulating Leptin and Risk of Pancreatic Cancer: A Pooled Analysis From 3 Cohorts. Am J Epidemiol 182: 187-97, 2015.

download

Houghton LC, Pollak MN, Tao Y, Tu YG, Black A, Bradwin G, Hoover RN, Troisi R. Similarity of Serum and Plasma Insulin-like Growth Factor Concentrations. Biomark Cancer. 2015 Jun 8: eCollection 2015.

download

Catsburg C, Gunter MJ, Tinker L, Chlebowski RT, Pollak M, Strickler HD, Cote ML, Page DL, Rohan TE. Serum IGFBP-2 and Risk of Atypical Hyperplasia of the Breast. J Cancer Epidemiol 2015, 2015.

download

Mu F, Hankinson SE, Schernhammer E, Pollak MN, Missmer SA. A Prospective Study of Insulin-Like Growth Factor 1, Its Binding Protein 3, and Risk of Endometriosis. Am J Epidemiol 182: 148-56, 2015.

download

Kordes S, Pollak MN, Zwinderman AH, Mathôt RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16: 839-47, 2015.

[see also favorable editorial comment [.pdf] - Lancet: 2015]

download

Blouin MJ, Bazile M, Birman E, Zakikhani M, Florianova L, Aleynikova O, Powell DR, Pollak M. Germ line knockout of IGFBP-3 reveals influences of the gene on mammary gland neoplasia. Breast Cancer Res Treat 149: 577-85, 2015.

download

Morita M, Gravel SP, Hulea L, Larsson O, Pollak M, St-Pierre J, Topisirovic I. mTOR coordinates protein synthesis, mitochondrial activity and proliferation. Cell Cycle 14: 473-80, 2015.

download

Cifarelli V, Lashinger LM, Devlin KL, Dunlap SM, Huang J, Kaaks R, Pollak MN, Hursting SD. Metformin and rapamycin reduce pancreatic cancer growth in obese prediabetic mice by distinct microRNA-regulated mechanisms. Diabetes 64: 1632-42, 2015.

download

Joerger M, van Schaik RH, Becker ML, Hayoz S, Pollak M, Cathomas R, Winterhalder R, Gillessen S, Rothermundt C. Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). Prostate Cancer Prostatic Dis 18: 167-72, 2015.

download

Cao Y, Nimptsch K, Shui IM, Platz EA, Wu K, Pollak MN, Kenfield SA, Stampfer MJ, Giovannucci EL. Prediagnostic plasma IGFBP-1, IGF-1 and risk of prostate cancer. Int J Cancer 136; 2418-26, 2015.

download

Assayag J, Pollak MN, Azoulay L. The Use of Aspirin and the Risk of Mortality in Patients with Prostate Cancer. J Urol 193: 1220-5, 2015.

download

Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: from mechanisms of action to therapies. Cell Metab 20: 953-966, 2014.

download

Gravel SP, Hulea L, Toban N, Birman E, Blouin MJ, Zakikhani M, Zhao Y, Topisirovic I, St-Pierre J, Pollak M. Serine deprivation enhances antineoplastic activity of biguanides. Cancer Res 74: 7521-33, 2014.

download

Chapman JA, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN. Competing risks of death in younger and older postmenopausal breast cancer patients. World J Clin Oncol 5: 1088-96, 2014.

download

Paxton RJ, Jung SY, Vitolins MZ, Fenton J, Paskett E, Pollak M, Hays-Grudo J, Hursting SD, Chang S. Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. Cancer Causes Control 25: 1427-37, 2014.

download

DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN. Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Breast Cancer Res Treat 148: 81-90, 2014.

download

Assayag J, Pollak MN, Azoulay L. Post-diagnostic use of beta-blockers and the risk of death in patients with prostate cancer. Eur J Cancer 50: 2838-45, 2014.

download

Andrzejewski S, Gravel SP, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2014 Aug 28. eCollection 2014.

download

Mayers JR, Wu C, Clish CB, Kraft P, Torrence ME, Fiske BP, Yuan C, Bao Y, Townsend MK, Tworoger SS, Davidson SM, Papagiannakopoulos T, Yang A, Dayton TL, Ogino S, Stampfer MJ, Giovannucci EL, Qian ZR, Rubinson DA, Ma J, Sesso HD, Gaziano JM, Cochrane BB, Liu S, Wactawski-Wende J, Manson JE, Pollak MN, Kimmelman AC, Souza A, Pierce K, Wang TJ, Gerszten RE, Fuchs CS, Vander Heiden MG, Wolpin BM. Elevated circulating branched chain amino acids are an early event in pancreatic adenocarcinoma development. Nat Med 20: 1193-8, 2014.

download

Bridges HR, Jones AJ, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J 462: 475-87, 2014.

download

Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L. The use of metformin in patients with prostate cancer and the risk of death. Cancer Epidemiol Biomarkers Prev 23: 2111-8, 2014.

download

Laskov I, Drudi L, Beauchamp MC, Yasmeen A, Ferenczy A, Pollak M, Gotlieb WH. Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer. Gynecol Oncol 134: 607-14, 2014.

download

Jacobs EJ, Newton CC, Silverman DT, Nogueira LM, Albanes D, Männistö S, Pollak M, Stolzenberg-Solomon RZ. Serum transforming growth factor-β1 and risk of pancreatic cancer in three prospective cohort studies. Cancer Causes Control 25:1083-91, 2014.

download

Pollak M. Overcoming Drug Development Bottlenecks With Repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. Nat Med 5: 591-593, 2014.

download

Joshua AM, Zannella VE, Downes MR, Bowes B, Hersey K, Koritzinsky M, Schwab M, Hofmann U, Evans A, van der Kwast T, Trachtenberg J, Finelli A, Fleshner N, Sweet J, Pollak M. A pilot 'window of opportunity' neoadjuvant study of metformin in localised prostate cancer. Prostate Cancer Prostatic Dis 17: 252-8, 2014.

download

Beasley JM, Wedick NM, Rajpathak SN, Xue X, Holmes MD, Gunter MJ, Wylie-Rosett J, Rohan TE, Pollak M, Kaplan RC, Hu FB, Sun Q, Strickler HD. Circulating IGF-axis protein levels and their relation with levels of plasma adipocytokines and macronutrient consumption in women. Growth Horm IGF Res 24: 142-9, 2014.

download

Lai GY, Giovannucci EL, Pollak MN, Peskoe SB, Stampfer MJ, Willett WC, Platz EA. Association of C-peptide and leptin with prostate cancer incidence in the Health Professionals Follow-up Study. Cancer Causes Control 25: 625-32, 2014.

download

Cao Y, Lindström S, Schumacher F, Stevens VL, Albanes D, Berndt SI, Boeing H, Bas Bueno-de-Mesquita H, Canzian F, Chamosa S, Chanock SJ, Diver WR, Gapstur SM, Gaziano JM, Giovannucci EL, Haiman CA, Henderson B, Johansson M, Marchand LL, Palli D, Rosner B, Siddiq A, Stampfer M, Stram DO, Tamimi R, Travis RC, Trichopoulos D, Willett WC, Yeager M, Kraft P, Hsing AW, Pollak M, Lin X, Ma J. Insulin-like Growth Factor Pathway Genetic Polymorphisms, Circulating IGF1 and IGFBP3, and Prostate Cancer Survival. J Natl Cancer Inst 106: 218, 2014.

download

De Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Antón-Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN. Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res 20: 1925-34, 2014.

download

Takeuchi A, Shiota M, Beraldi E, Thaper D, Takahara K, Ibuki N, Pollak M, Cox ME, Naito S, Gleave ME, Zoubeidi A. Insulin-like growth factor-I induces CLU expression through Twist1 to promote prostate cancer growth. Mol Cell Endocrinol 1: 117-125, 2014.

download

Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-Katib W, Shepherd LE, Han L, Wilson CF, Pritchard KI, Pollak MN, Chambers AF. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res 16: 2014.

download

Borugian MJ, Spinelli JJ, Gordon PB, Abanto Z, Brooks-Wilson A, Pollak MN, Warren LJ, Hislop TG, Gallagher RP. Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada). Cancer Causes Control 25: 385-94, 2014.

download

Mireuta M, Birman E, Barmash M, Pollak M. Quantification of Binding of IGF-1 to BI 836845, a Candidate Therapeutic Antibody Against IGF-1 and IGF-2, and Effects of This Antibody on IGF-1:IGFBP-3 Complexes in Vitro and in Male C57BL/6 Mice. Endocrinology 155: 703-15, 2014.

download

Rothermundt C, Hayoz S, Templeton AJ, Winterhalder R, Strebel RT, Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff JH, Cathomas R, Gillessen S. Metformin in Chemotherapy-naive Castration-resistant Prostate Cancer: A Multicenter Phase 2 Trial (SAKK 08/09). Eur Urol 66: 468-74, 2014.

download

Bensimon L, Yin H, Suissa S, Pollak MN, Azoulay L. Type 2 diabetes and the risk of mortality among patients with prostate cancer. Cancer Causes Control 25: 329-38, 2014.

download

Muhlbradt E, Ma J, Severi G, Ortner E, Hayes V, Hoang HN, Stampfer M, Giles G, Pollak M, Gelmann EP. Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. Genes Cancer 4: 535-45, 2013.

download

Hvid H, Blouin MJ, Birman E, Damgaard J, Poulsen F, Fels JJ, Fledelius C, Hansen BF, Pollak M. Treatment with Insulin Analog X10 and IGF-1 Increases Growth of Colon Cancer Allografts. PLoS One. 2013 Nov 18.

download

Morita M, Gravel SP, Chénard V, Sikström K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, McLaughlan S, Nouet Y, Pause A, Pollak M, Gottlieb E, Larsson O, St-Pierre J, Topisirovic I, Sonenberg N. mTORC1 Controls Mitochondrial Activity and Biogenesis through 4E-BP-Dependent Translational Regulation. Cell Metab 18: 698-711, 2013.

download

Friedbichler K, Hofmann MH, Kroez M, Ostermann E, Lamche HR, Koessl C, Borges E, Pollak MN, Adolf G, Adam PJ. Pharmacodynamic and antineoplastic activity of BI 836845, a fully human IGF ligand neutralizing antibody, and mechanistic rationale for combination with rapamycin. Mol Cancer Ther 13: 399-409, 2013.

download

Van Dang C, Pollak M. Why Cancer & Metabolism? Why now? Cancer Metab 1: 1, 2013.

download

Pettersson A, Lis RT, Meisner A, Flavin R, Stack EC, Fiorentino M, Finn S, Graff RE, Penney KL, Rider JR, Nuttall EJ, Martin NE, Sesso HD, Pollak M, Stampfer MJ, Kantoff PW, Giovannucci EL, Loda M, Mucci LA. Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. J Natl Cancer Inst 105: 1881-90, 2013.

download

Li R, Montpetit A, Rousseau M, Wu SY, Greenwood CM, Spector TD, Pollak M, Polychronakos C, Richard JB. Somatic point mutations occurring early in development: a monozygotic twin study. J Med Genet 51: 28-34, 2013.

download

Ahern TP, Hankinson SE, Willett WC, Pollak MN, Eliassen AH, Tamimi RM. Plasma C-Peptide, Mammographic Breast Density, and Risk of Invasive Breast Cancer. Cancer Epidemiol Biomarkers Prev 22: 1786-1796, 2013.

download

Pollak M. Potential applications for biguanides in oncology. J Clin Invest 123: 3693-700, 2013.

download

Morita M, Gravel S-P, Chénard V, Sikström K, Zheng L, Alain T, Gandin V, Avizonis D, Arguello M, Zakaria C, McLaughlan S, Nouet Y, Pause A, Pollak M, Gottlieb E, Larsson O, St-Pierre J, Topisirovic I, Sonenberg N. Translational control of the mitochondrion. Cell Metabolism 2013. September 2013. In press.

download

Zu K, Martin NE, Fiorentino M, Flavin R, Lis RT, Sinnott JA, Finn SP, Penney KL, Ma J, Fazli L, Gleave ME, Bismar TA, Stampfer MJ, Pollak MN, Loda M, Mucci LA, Giovannucci EL. Protein expression of PTEN, insulin-like growth factor I receptor (IGF1R), and lethal prostate cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 22: 1984-93, 2014.

download

Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and colorectal cancer incidence in patients with type 2 diabetes mellitus. Cancer Epidemiol Biomarkers Prev 22: 1877-1883, 2013.

download

Grimaldi-Bensouda L, Cameron D, Marty M, Barnett AH, Penault-Llorca F, Pollak M, Charbonnel B, Riddle M, Mignot L, Boivin JF, Khachatryan A, Rossignol M, Bénichou J, Alpérovitch A, Abenhaim L. Risk of breast cancer by individual insulin use - an international multicenter study. Diabetes Care 37: 134-43, 2013.

download

Martin-Montalvo A, Mercken EM, Mitchell SJ, Palacios HH, Mote PL, Scheibye-Knudsen M, Gomes AP, Ward TM, Minor RK, Blouin MJ, Schwab M, Pollak M, Zhang Y, Yu Y, Becker KG, Bohr VA, Ingram DK, Sinclair DA, Wolf NS, Spindler SR, Bernier M, de Cabo R. Metformin improves healthspan and lifespan in mice. Nat Commun 4, 2013. 

download

Wolpin BM, Bao Y, Qian ZR, Wu C, Kraft P, Ogino S, Stampfer MJ, Sato K, Ma J, Buring JE, Sesso HD, Lee IM, Gaziano JM, McTiernan A, Phillips LS, Cochrane BB, Pollak MN, Manson JE, Giovannucci EL, Fuchs CS. Hyperglycemia, Insulin Resistance, Impaired Pancreatic β-Cell Function, and Risk of Pancreatic Cancer. J Natl Cancer Inst 105: 1027-35, 2013. 

download

Leprivier G, Remke M, Rotblat B, Dubuc A, Mateo AR, Kool M, Agnihotri S, El-Naggar A, Yu B, Prakash Somasekharan S, Faubert B, Bridon G, Tognon CE, Mathers J, Thomas R, Li A, Barokas A, Kwok B, Bowden M, Smith S, Wu X, Korshunov A, Hielscher T, Northcott PA, Galpin JD, Ahern CA, Wang Y, McCabe MG, Collins VP, Jones RG, Pollak M, Delattre O, Gleave ME, Jan E, Pfister SM, Proud CG, Derry WB, Taylor MD, Sorensen PH. The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. Cell 153: 1064-79, 2013.

download

Takahara K, Ibuki N, Ghaffari M, Tearle H, Ong CJ, Azuma H, Gleave ME, Pollak M, Cox ME. The influence of growth hormone/insulin-like growth factor deficiency on prostatic dysplasia in pbARR2-Cre, PTEN knockout mice. Prostate Cancer Prostatic Dis 16: 239-47, 2013.

download

Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers JR, Schwab M, Bellinger G, Csibi A, Patnaik A, Blouin MJ, Cantley LC, Guarente LP, Blenis J, Pollak MN, Olumi AF, Vander Heiden M, Stephanopoulos G. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 73: 4429-4438, 2013.

download

Moiseeva O, Deschênes-Simard X, Pollak M, Ferbeyre G. Metformin, aging and cancer. Aging 5: 330-1, 2013.

download

Palumbo MO, Kavan P, Miller WH Jr, Panasci L, Assouline S, Johnson N, Cohen V, Patenaude F, Pollak M, Jagoe RT, Batist G. Systemic cancer therapy: achievements and challenges that lie ahead. Front Pharmacol 4: 57, 2013.

download

Vandersluis AD, Venier NA, Colquhoun AJ, Sugar L, Pollak M, Kiss A, Fleshner NE, Klotz LH, Venkateswaran V. Exercise does not counteract the effects of a "westernized" diet on prostate cancer xenografts. Prostate 73: 1223-32, 2013.

download

Assayag J, Yin H, Benayoun S, Pollak MN, Suissa S, Azoulay L. Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer. Cancer Causes Control 24: 839-45, 2013.

download

Pollak M. Targeting oxidative phosphorylation: why, when, and how. Cancer Cell 23: 263-4, 2013.

download

Moiseeva O, Deschenes-Simard X, St-Germian E, Igelmann S, Huot G, Cadar AE, Bourdeau V, Pollak MN, Ferbeyre G. Metformin inhibits the senescence-associated secretory phenotype by interfering with IKK/NF-κB activation. Aging Cell 12: 489-98, 2013.

download

Hofmann J, Liao L, Pollak M, Wang Ye, Pfeiffer R, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue M. A prospective study of circulating adipokine levels and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 22: 472, 2013.

download

Bao Y, Giovannucci E, Kraft P, Qian ZR, Wu C, Ogino S, Gaziano JM, Stampfer MJ, Ma J, Buring JE, Sesso H, Lee IM, Rifai N, Pollak MN, Jiao L, Lessin LS, Cochrane BB, Manson JE, Fuchs CS, Wolpin BM. Inflammatory plasma markers and pancreatic cancer risk: a prospective study of 5 US cohorts. Cancer Epidemiol Biomarkers Prev 105: 95-103, 2013.

download

Song Y, Chavarro JE, Cao Y, Qiu W, Mucci L, Sesso HD, Stampfer MJ, Giovannucci E, Pollak M, Liu S, Ma J. Whole milk intake is associated with prostate cancer-specific mortality among U.S. male physicians. J Nutr 143: 189-96, 2013.

download

Neuhouser ML, Platz EA, Till C, Tangen CM, Goodman PJ, Kristal A, Parnes Hl, Tao Y, Figg WD, Lucia MS, Hoque A, Hsing AW, Thompson IM, Pollak M. Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) 6: 91-9, 2013.

download

Lubik AA, Gunter JH, Hollier BG, Fazli L, Ettinger S, Stylianou N, Adomat H, Hendy SC, Gleave M, Pollak MN, Herington A, Nelson CC. Insulin-like growth factor-2 increases de novo steroidogenesis in prostate cancer cells. Endocr Relat Cancer 20: 173-86, 2013.

download

Liao LM, Weinstein SJ, Pollak M, Li Z, Virtamo J, Albanes D, Chow WH, Purdue MP. Pre-diagnostic circulating adipokine concentrations and risk of renal cell carcinoma. Carcinogenesis 34: 109-12, 2013.

download

Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 36: 124-9, 2013.

download

Dallal CM, Brinton LA, Bauer DC, Buist DS, Cauley JA, Hue TF, Lacroix A, Tice JA, Chia VM, Falk R, Pfeiffer R, Pollak MN, Veenstra TD, Xu X, Lacey JV. Obesity-related hormones and endometrial cancer among postmenopausal women: a nested case-control study within the B~FIT cohort. Endocr Relat Cancer 20: 151-60, 2013. 

download

Bao Y, Giovannucci EL, Kraft P, Stamfer MJ, Ogino S, Ma J, Buring JE, Sesson HD, Lee IM, Gaziano JM, Rifai N, Pollak MN, Cochrane BB, Kaklamani V, Lin JH, Manson JE, Fuchs CS, Wolpin BM. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst 105: 95-103, 2013.

download

Evdokimova V, Tognon CE, Benatar T, Yang W, Krutikov K, Pollak M, Sorensen PH, Seth A. IGFBP7 binds to the IGF-1 receptor and blocks its activation by insulin-like growth factors. Sci Signal 5: ra92, 2012.

download

Zakikhani M, Bazile M, Hashemi S, Javeshghani S, Avizonis D, Pierre JS, Pollak MN. Alterations in Cellular Energy Metabolism Associated with the Antiproliferative Effects of the ATM Inhibitor KU-55933 and with Metformin. PLoS One 7: e49513, 2012.

download

Eichholzer M, Platz EA, Bienstock JL, Monsegue D, Akereyeni F, Hollis BW, Horst R, Rifai N, Pollak MN, Barbir A, Agurs-Collins T, Rohrmann S. Racial variation in vitamin D cord blood concentration in white and black male neonates. Cancer Causes Control. 2012 Nov 9.

download

Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, Severi G, Yuan JM, Anderson KC, Pollak M, Rifai N, Hartge P, Landgren O, Lessin L, Virtamo J, Wallace RB, Manson JE, Colditz GA. Pre-diagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood. 2012 Oct 16.

download

Rice MS, Tworoger SS, Rosner BA, Pollak MN, Hankinson SE, Tamimi RM. Insulin-like growth factor-1, insulin-like growth factor-binding  protein-3, growth hormone, and mammographic density in the Nurses’ Health Studies. Breast Cancer Res Treat. 2012 Oct 21.

download

Javeshghani S, Zakikhani M, Austin S, Bazile M, Blouin MJ, Topisirovic I, St-Pierre J, Pollak MN. Carbon source and myc expression influence the antiproliferative actions of metformin. Cancer Res. 2012 Oct 4.

download

Liao LM, Weinstein SJ, Pollak M, Li Z, Virtamo J, Albanes D, Chow WH, Purdue MP. Pre-diagnostic circulating adipokine concentrations and risk of renal cell carcinoma. Carcinogenesis. 2012 Oct 6.

download

Hofmann JN, Liao LM, Pollak MN, Wang Y, Pfeiffer RM, Baris D, Andreotti G, Lan Q, Landgren O, Rothman N, Purdue MP. A prospective study of circulating adipokine levels and risk of multiple myeloma. Blood. 2012 Sep 24.

download

Smiechowski BB, Azoulay L, Yin H, Pollak MN, Suissa S. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 36: 124-9, 2013. 

download

Pollak M. Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov 2: 778-90, 2012. [Recognized by the AACR journals as one of the most highly-cited Cancer Prevention Research articles published in 2012]

download

Runchey SS, Pollak MN, Valsta LM, Coronado GD, Schwarz Y, Breymeyer KL, Wang C, Wang CY, Lampe JW, Neuhouser ML. Glycemic load effect on fasting and post-prandial serum glucose, insulin, IGF-1 and IGFBP-3 in a randomized, controlled feeding study. Eur J Clin Nutr. 2012 Aug 15. 

download

Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor in breast cancer subtypes. Breast Cancer Res Treat 132: 131-42, 2012.

download

Tognon CE, Martin MJ, Moradian A, Trigo G, Rotblat B, Cheng SW, Pollard M, Uy E, Chow C, Carboni JM, Gottardis MM, Pollak M, Morin GB, Sorensen PH. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene 31: 1334-40, 2012.

download

Gao Y, Katki H, Graubard B, Pollak M, Martin M, Tao Y, Schoen RE, Church T, Hayes RB, Greene MH, Berndt SI. Serum IGF1, IGF2, and IGFBP3 and risk of advanced colorectal adenoma. Int J Cancer 131: E105-13, 2012.

download

Johnson JA, Carstensen B, Witte D, Bowker SL, Lipscombe L, Renehan AG; Diabetes and Cancer Research Consortium (Dr. Pollak is a member). Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia 55: 1607-18, 2012.

download

Renehan AG, Yeh HC, Johnson JA, Wild SH, Gale EA, Moller H; Diabetes and Cancer Research Consortium (Dr. Pollak is a member). Diabetes and cancer (2): evaluating the impact of diabetes on mortality in patients with cancer. Diabetologia 55: 1619-32, 2012.

download

*Hvid H, Fendt SM, Blouin MJ, Birman E, Voisin G, Svendsen AM, Frank R, Vander Heiden MG, Stephanopoulos G, Hansen BF, Pollak MN. Stimulation of MC38 tumor growth by insulin analog X10 involves the serine synthesis pathway. Endocr Relat Cancer. 2012 Jun 8.

download

Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 344: e3645, 2012.

download

Jones LW, Antonelli J, Masko EM, Broadwater G, Lascola CD, Fels D, Dewhirst MW, Dyck JR, Nagendran J, Flores CT, Betof AS, Nelson ER, Pollak M, Dash RC, Young ME, Freedland SJ. Exercise modulation of the host – tumor interaction in an orthotopic model of murine prostate cancer. J Appl Physiol. 2012 May 17.

download

Larsson O, Morita M, Topisirovic I, Alain T, Blouin MJ, Pollak M, Sonenberg N. Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci USA. 2012 May 18.

download

Jenkins CR, Schevchuk OO, Giambra V, Lam SH, Carboni JM, Gottardis MM, Holzenberger M, Pollak M, Humphries RK, Weng AP. IGF signaling contributes to malignant transformation of hematopoietic progenitors by the MLL-AF9 oncoprotein. Exp Hematol. 2012 May 18.

download

Colquhoun AJ, Venier NA, Vandersluis AD, Besla R, Sugar LM, Kiss A, Fleshner NE, Pollak M, Klotz LH, Venkateswaran V. Metformin enhances the antiproliferative and apoptotic effect of bicalutamide in prostate cancer. Prostate Cancer Prostatic Dis. 2012 May 22.

download

Fung TT, Hu FB, Schulze M, Pollak M, Wu T, Fuchs CS, Giovannucci E. A dietary pattern that is associated with C-peptide and risk of colorectal cancer in women. Cancer Causes Control 23: 959-65, 2012.

download

Gunter JH, Lubik AA, McKenzie I, Pollak M, Nelson CC. The interactions between insulin and androgens in progression to castrate-resistant prostate cancer. Adv Urol. 2012 Apr 3.

download

Chi KN, Gleave ME, Fazli L, Goldenberg SL, So A, Kollmannsberger C, Murray N, Tinker AV, Pollak MN. A phase 2 pharmacodynamic study of pre-operative figitumumab in patients with localized prostate cancer. Clin Cancer Res. 2012 May 2.

download

Rajpathak SN, HE M, Sun Q, Kaplan RC, Muzumdar R, Rohan TE, Gunter MJ, Pollak M, Kim M, Pessin JE, Beasley J, Wylie-Rosett J, Hu FB, Strickler HD. Insulin-like growth factor axis and risk of type 2 diabetes in women. Diabetes. 2012 May 3.

download

Kaplan RC, Buzkova P, Cappola AR, Strickler HD, McGinn AP, Mercer LD, Arnold AM, Pollak MN, Newman AB. Decline in circulating insulin-like growth factors and mortality in older adults: Cardiovascular Health Study All-Stars Study. J Clin Endocrinol Metab. 2012 Mar 22.

download

Pollak M. Metformin and pancreatic cancer: a clue requiring investigation. Clin Cancer Res 18: 2723-5, 2012.

download

Pollak M, Gonzalez-Angulo AM. Metformin and hepatic carcinogenesis. Cancer Prev Res (Phila). 2012 Mar 31.

download

Rice MS, Tamimi RM, Connolly JL, Collins LC, Shen D, Pollak MN, Rosner B, Hankinson SE, Tworoger SS. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and lobule type in the Nurses’ Health Study II. Breast Cancer Res 14: R44, 2012.

download

Zhang X, Giovannucci EL, Wu K, Smith-Warner SA, Fuchs CS, Pollak M, Willett WC, Ma J. Magnesium intake, plasma C-peptide, and colorectal cancer incidence in US women: a 28-year follow-up study. Br J Cancer. 2012 Mar 13.

download

Faupel-Badger JM, Wang Y, Staff AC, Karumanchi SA, Stanczyk FZ, Pollak M, Hoover RN, Troisi R. Maternal and cord steroid sex hormones, angiogenic factors, and insulin-like growth factor axis in African-American preeclamptic and uncomplicated pregnancies. Cancer Causes Control. 2012 Mar 15.

download

Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012 Feb 16.

download

Ollberding NJ, Cheng I, Wilkens LR, Henderson BE, Pollak MN, Kolonel LN, Le Marchand L. Genetic variants, prediagnostic levels of insulin-like growth factors, insulin and glucose, and the risk of colorectal cancer: The Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev. 2012 Feb 21.

download

Agurs-Collins T, Rohrmann S, Sutcliffe C, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN, Platz EA. Racial variation in umbilical cord blood sex steroid hormones and the insulin-like growth factor axis in African-American and white female neonates. Cancer Causes Control. 2012 Jan 18.

download

Algire C, Moiseeva O, Deschenes-Simard X, Amrein L, Petruccelli LA, Birman E, Viollet B, Ferbeyre G, Pollak MN. Metformin reduces endogenous reactive oxygen species and associated DNA damage. Cancer Prev Res (Phila) 5: 536-43, 2012. [Recognized by the AACR journals as one of the most highly-cited Cancer Prevention Research articles published in 2012] 

download

Pollak M. The insulin receptor/insulin-like growth factor receptor family as a therapeutic target in oncology. Clinical Cancer Res 18: 40-50, 2012.

download

Dhillon PK, Penney KL, Schumacher F, Rider JR, Sesso HD, Pollak M, Fiorentino M, Finn S, Loda M, Rifai N, Mucci LA, Giovannucci E, Stampfer MJ, Ma J. Common polymorphisms in the adiponectin and its receptor genes, adiponectin levels and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 20: 2618-27, 2011.

download

Wu K, Feskanich D, Fuchs CS, Chan AT, Willett WC, Hollis BW, Pollak MN, Giovannucci. Interactions between plasma levels of 25-hydroxyvitamin D, insulin-like growth factor (IGF)-1 and c-peptide with risk of colorectal cancer. PLoS One 6: e28520, 2011.

download

Dool C, Mashhedi H, Zakikhani M, David S, Zhao Y, Birman E, Carboni JM, Gottardis M, Blouin MJ, Pollak MN. IGF-1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin responsive breast cancer. Endocr Relat Cancer. 2011 Sep 26.

download

Faupel-Badger JM, Wang Y, Karumanchi SA, Stanczyk F, Pollak M, McElrath T, Hoover RN, Troisi R. Associations of pregnancy characteristics with maternal and cord steroid hormones, angiogenic factors, and insulin-like growth factor axis. Cancer Causes Control 22: 1587-95, 2011.

download

Segal Ed, Yasmeen A, Beauchamp MC, Rosenblatt J, Pollak M, Gotlieb WH. Relevance of the OCT1 transporter to the antineoplastic effect of biguanides. Biochem Biophys Res Commun 414: 694-9, 2011.

download

Saad F, Hotte S, North S, Eigl B, Chi K, Czaykowski P, Wood L, Pollak M, Berry S, Lattouf JB, Mukherjee SD, Gleave M, WInquist E; for the Canadian Uro-Oncology Group. Randomized phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin Cancer Res 17: 5765-73, 2011.

download

Zhang X, Giovannucci EL, Smith-Warner SA, Wu K, Fuchs CS, Pollak M, Willett WC, Ma J. A prospective study of intakes of zinc and heme iron and colorectal cancer risk in men and women. Cancer Causes Control 22: 1627-37, 2011.

download

Lubik AA, Gunter JH, Hendy SC, Locke JA, Adomat HH, Thompson V, Herington A, Gleave ME, Pollak M, Nelson CC. Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res 71: 5754-64, 2011.

download

Tognon CE, Martin MJ, Moradian A, Trigo G, Rotblat B, Cheng SW, Pollard M, Uy E, Chow C, Carboni JM, Gottardis MM, Pollak M, Morin GB, Sorensen PH. A tripartite complex composed of ETV6-NTRK3, IRS1 and IGF1R is required for ETV6-NTRK3-mediated membrane localization and transformation. Oncogene 31: 1334-40, 2011.

download

Medyouf H, Gusscott S, Wang H, Tseng JC, Wai C, Nemirovsky O, Trumpp A, Pflumio F, Carboni J, Gottardis M, Pollak M, Kung AL, Aster JC, Holzenberger M, Weng AP. High-level  IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signalling. J Exp Med 208: 1809-22, 2011.

download

Poole EM, Tworoger SS, Hankinson SE, Schernhammer ES, Pollak MN, Baer HJ. Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3. Am J Epidemiol 174: 642-51, 2011.

download

Lipton A, Chapman JA, Demers L, Shepherd LE, Han L, Wilson CF, Pritchard KI, Leitzel KE, Ali SM, Pollak M. Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA. 14. J Clin Oncol 29: 3605-10, 2011.

download

Suissa A, Azoulay L, Dell’aniello S, Evans M, Vora J, Pollak M. Long-term effects of insulin glargine on the risk of breast cancer. Diabetologia 54: 2254-62, 2011.

 download

Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H. Insulin-like growth factor receptor in breast cancer subtypes. Breast Cancer Res Treat 132: 131-42, 2011. 

 download

Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by metformin in epithelial ovarian cancer: Involvement of the Bcl-2 family proteins. Gynecol Oncol 121: 492-8, 2011.

download

Ng K, Sargent DJ, Goldberg RM, Meyerhardt JA, Green EM, Pitot HC, Hollis BW, Pollak MN, Fuchs CS. Vitamin D status in patients with stage IV colorectal cancer: Findings from intergroup trial N9741. J Clin Oncol 29: 1599-606, 2011.

download

Mireuta M, Hancock MA, Pollak M. Binding between insulin-like growth factor 1 and insulin-like growth factor binding protein 3 is not influenced by glucose or 2-deoxy-D-glucose. J Biol Chem 286:16567-73, 2011.

download

Kaplan RC, Petersen AK, Chen MH, Teumer A, Glazer NL, Doring A, Lam CS, Friedrich N, Newman A, Muller M, Yang Q, Homuth G, Cappola A, Klopp N, Smith H, Ernst F, Psaty BM, Wichmann HE, Sawyer DB, Biffar R, Rotter JI, Gieger C, Sullivan LS, Volzke H, Rice K, Spyroglou A, Kroemer HK, Ida Chen YD, Manolopoulou J, Nauck M, Strickler HD, Goodarzi MO, Reincke M, Pollak MN, Bidlingmaier M, Vasan RS, Wallaschofski H. A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet 20: 1241-51, 2011.

download

Douglas JB, Silverman DT, Weinstein SJ, Graubard BI, Pollak MN, Tao Y, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Serum C-reactive protein and risk of pancreatic cancer in two nested, case-control studies. Cancer Epidemiol Biomarkers Prev 20: 359-69, 2011.

download

Azoulay L, Dell'Aniello S, Gagnon B, Pollak M, Suissa S. Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev 20: 337-44, 2011.

download

Tognon CE, Somasiri AM, Evdokimova VE, Trigo G, Uy EE, Melnyk N, Carboni JM, Gottardis MM, Roskelley CD, Pollak M, Sorensen PH. ETV6-NTRK3-mediated breast epithelial cell transformation is blocked by targeting the IGF1R signaling pathway. Cancer Res 71: 1060-70, 2011.

download

Bordeleau L, Lipscombe L, Lubinski J, Ghadirian P, Foulkes WD, Neuhausen S, Ainsworth P, Pollak M, Sun P, Narod SA; the Hereditary Breast Cancer Clinical Study Group. Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations. Cancer 117: 1812-8, 2011.

download

Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, Paz-Ares LG, Novello S, Blakely J, Langer CJ, Pollak MN. Pre-treatment levels of circulating free IGF-I identify NSCLC patients who derive clinical benefit from figitumumab. Br J Cancer 104: 68-74, 2011.

download

Algire C, Amrein L, Bazile M, David S, Zakikhani M, Pollak M. Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. Oncogene 30: 1174-82, 2011.

download

Takahara K, Tearle H, Ghaffari M, Gleave ME, Pollak M, Cox ME. Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression. Prostate 71: 525-37, 2011.

download

Nimptsch K, Platz EA, Pollak MN, Kenfield SA, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. Int J Cancer 128: 660-7, 2011.

download

Pritchard KI, Shepherd LE, Chapman JW, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O’Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol 29: 3869-76, 2011.

download

Mashhedi H, Blouin MJ, Zakikhani M, David S, Zhao Y, Bazile M, Birman E, Algire C, Aliaga A, Bedell BJ, Pollak M. Metformin abolishes increased tumor (18)F-2-Fluoro-2-Deoxy-D-Glucose uptake associated with a high-energy diet. Cell Cycle 10: 2770-8, 2011.

download

Potratz JC, Saunders DN, Wai DH, Ng TL, McKinney SE, Carboni JM, Gottardis MM, Triche TJ, Jurgens H, Pollak MN, Aparicio SA, Sorensen PH. Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res 70: 8770-81, 2010.

download

Grimaldi-Bensouda L, Marty M, Pollak M, Cameron D, Riddle M, Charbonnel B, Barnett AH, Boffetta P, Boivin JF, Evans M, Rossignol M, Benichou J, Abenhaim L; ISICA group. The international study of insulin and cancer. Lancet 376: 769-70, 2010.

download

Pollak M. Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila Pa) 3: 1060-5, 2010.

download

Thomas JA 2nd, Antonelli JA, Lloyd JC, Masko EM, Poulton SH, Phillips TE, Pollak M, Freedland SJ. Effect of intermittent fasting on prostate cancer tumor growth in a mouse model. Prostate Cancer Prostatic Dis 13: 350-5, 2010.

download

Major JM, Stolzenberg-Solomon RZ, Pollak MN, Snyder K, Virtamo J, Albanes D. Insulin-like growth factors and liver cancer risk in male smokers. Br J Cancer 103: 1089-32, 2010.

download

Johnson JA, Pollak M. Insulin, glucose and the increased risk of cancer in patients with type 2 diabetes. Diabetologia 53: 2086-8, 2010.

download

Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, Petroulakis E, Robichaud N, Pollak M, Gaboury LA, Pandolfi PP, Saad F, Sonenberg N. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA 107: 14134-9, 2010.

download

Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 19: 2298-306, 2010.

download

Canzian F, Cox DG, Setiawan VW, Stram DO, Ziegler RG, Dossus L, Beckmann L, Blanche H, Barricarte A, Berg CD, Bingham S, Buring J, Buys SS, Calle EE, Chanock SJ, Clavel-Chapelon F, Delancey JO, Diver WR, Dorronsoro M, Haiman CA, Hallmans G, Hankinson SE, Hunter DJ, Husing A, Isaacs C, Khaw KT, Kolonel LN, Kraft P, Le Marchand L, Lund E, Overvad K, Panico S, Peeters PH, Pollak M, Thun MJ, Tjonneland A, Trichopoulous D, Tumino R, Yeager M, Hoover RN, Riboli E, Thomas G, Henderson BE, Kaaks R, Feigelson HS. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI Breast and Prostate Cancer Cohort Consortium. Hum Mol Genet 19: 3873-84, 2010.

download

Hou M, Venier N, Sugar L, Musquera M, Pollak M, Kiss A, Fleshner N, Klotz L, Venkateswaran V. Protective effect of metformin in CD1 mice placed on a high carbohydrate-high fat diet. BiochemBiophys Res Commun 397: 537-42, 2010.

download

Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin 60: 207-21, 2010.

download

Inoue T, Zakikhani, David S, Algire C, Blouin MJ, Pollak M. Effects of castration on insulin levels and glucose tolerance in the mouse differ from those in man. Prostate 70: 1628-35, 2010.

download

Major JM, Pollak MN, Snyder K, Virtamo J, Albanes D. Insulin-like growth factors and risk of kidney cancer in men. Br J Cancer 103: 132-5, 2010.

download

Pollak M. Beyond steroid hormones: the new cancer endocrinology. Lancet Oncol 11: 501-2, 2010

download

Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolone LN, Tjonneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, Palli D, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J; {dagger}On behalf of the NCI Breast &Prostate Cancer Cohort Consortium. A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Human Mol Genet 19: 3089-101, 2010.

download

Mireuta M, Darnel A, Pollak M. IGFBP-2 expression in MCF-7 cells is regulated by the PI3K/AKT/mTOR pathway through Sp1-induced increase in transcription. Growth Factors 28: 243-55, 2010.

download

Okereke OI, Kurth T, Pollak MN, Gaziano JM, Grodstein F. Fasting plasma insulin, c-peptide and cognitive change in older men without diabetes: results from the Physicians’ Health Study II. Neuroepidemiology 34: 200-7, 2010.

download

Pollak M, Russell-Jones D. Insulin analogues and cancer risk: cause for concern or cause célèbre? Int J Clin Pract 64: 628-36, 2010.

download

Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer 17: 351-60, 2010.

download

Blouin MJ, Zhao Y, Zakikhani M, Algire C, Piura E, Pollak M. Loss of function of PTEN alters the relationship between glucose concentration and cell proliferation, increases glycolysis, and sensitizes cells to 2-deoxyglucose. Cancer Lett 298: 246-253, 2010.

download

Neuhouser ML, Till C, Kristal A, Goodman P, Hoque A, Platz EA, Hsing AW, Albanes D, Parnes HL, Pollak M. Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the prostate cancer prevention trial. Cancer Prev Res (Phila Pa) 3: 279-89, 2010.

download

Gill JK, Wilkens LR, Pollak MN, Stanczyk FZ, Kolonel LN. Androgens, growth factors, and risk of prostate cancer: the multiethnic cohort. Prostate 70: 906-15, 2010.

download

Flaig TW, Glode M, Gustafson D, van Bokhoven A, Tao Y, Wilson S, Su LJ, Li Y, Harrison G, Agarwal R, Crawford ED, Lucia MS, Pollak M. A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate 70: 848-55, 2010.

download

Zakikhani M, Blouin MJ, Piura E, Pollak MN. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123: 271-9, 2010.

download

Mucci LA, Stark JR, Pollak MN, Li H, Kurth T, Stampfer MJ, Ma J. Plasma levels of acid-labile subunit, free insulin-like growth factor-I, and prostate cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 19: 484-91, 2010.

download

Tsilidis KK, Brancati FL, Pollak MN, Rifai N, Clipp SL, Hoffman-Bolton J, Helzlsouer KJ, Platz EA. Metabolic syndrome components and colorectal adenoma in the CLUE II cohort. Cancer Causes Control 21: 1-10, 2010.

download

Khalid S, Hwang D, Babichev Y, Kolli R, Altamentova S, Koren S, Goodwin PJ, Ennis M, Pollak M, Sonenberg N, Fantus IG. Evidence for a tumor promoting effect of high-fat diet independent of insulin resistance in HER2/Neu mammary carcinogenesis. Breast Cancer Res Treat 122: 647-59, 2010.

download

Barbieri M, Paolisso G, Kimura M, Gardner JP, Boccardi V, Papa M, Hjelmborg JV, Christensen K, Brimacombe M, Nawrot TS, Staessen JA, Pollak MN, Aviv A. Higher circulating levels of igf-1 are associated with longer leukocyte telomere length in healthy subjects. Mech Ageing Dev 130: 771-6, 2009

download

Karp DD, Pollak MN, Cohen RB, Eisenberg PD, Haluska P, Yin D, Lipton A, Demers L, Leitzel K, Hixon ML, Terstappen LW, Garland L, Paz-Ares LG, Cardenal F, Langer CJ, Gualberto A. Safety, pharmacokinetics, and pharmacodynamics of the insulin-like growth factor type 1 receptor inhibitor Figitumumab (CP-751,871) in combination with Paclitaxel and Carboplatin. J Thorac Oncol 4: 1397-403, 2009.

download

Gualberto A, Pollak M. Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug targets 10: 923-36, 2009.

download

Beauchamp MC, Knafo A, Yasmeen A, carboni JM, Gottardis MM, Pollak MN, Gotlieb WH. BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide. Gynecol Oncol 115: 193-8, 2009.

download

Pollak M. Macronutrient intake and cancer: how does dietary restriction influence tumor growth and why should we care? Cancer Prev Res(Phila Pa) 2: 698-701, 2009.

download

Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 28: 3009-21, 2009.

download

Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, Pollak MN, Rosner B, Tamimi RM. Genetic variation and circulating levels of IGF-I and IGFBP-3 in relation to risk of proliferative benign breast disease. Int J Cancer 126: 180-90, 2009.

download

Dowling RJ, Pollak M, Sonenberg N. Current status and challenges associated with targeting mTOR for cancer therapy. BioDrugs 23: 77-91, 2009.

download

Mavropoulos JC, Buschemeyer WC 3rd, Tewari AK, Fokhfeld D, Pollak M, Zhao Y, Febbo PG, Cohen P, Hwang D, Devi G, Demark-Wahnefried W, Westman EC, Peterson BL, PIzzo SV, Freedland SJ. The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila Pa) 2: 557-65, 2009.

download

Rohrmann S, Sutcliffe CG, Bienstock JL, Monsegue D, Akereyeni F, Bradwin G, Rifai N, Pollak MN, Agurs-Collins T, Platz EA. Racial variation in sex steroid hormones and the insulin-like growth factor axis in umbilical cord blood of male neonates. Cancer Epidemiol Biomarkers Prev 18:1484-91, 2009.

download

Pollak, M. Do cancer cells care if their host is hungry? Cell Metab 9: 401-3, 2009.

download

Kaplan RC, Fitzpatrick AL, Pollak MN, Gardner JP, Jenny NS, McGinn AP, Kuller LH, Strickler HD, Kimura M, Psaty BM, Aviv A. Insulin-like growth factors and leukocyte telomere length: The cardiovascular health study. J Gerontol A Biol Sci Med Sci 64: 1103-6, 2009.

download

Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M. Insulin receptor expression by human prostate cancers. The Prostate 69: 33-40, 2009.

download

Pollak, M. Aging, IGF-1, and diet. Aging Cell 8: 214, 2009.

download

Avnet S, Sciacca L, Salerno M, Gancitano G, Cassarino MF, Longhi A, Zakikhani M, Carboni JM, Gottardis M, Giunti A, Pollak M, Vigneri R, Baldini N. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res 69: 2443-52, 2009.

download

Pollak M. Energy metabolism, cancer risk, and cancer prevention. Recent Results Cancer Res 181: 51-4, 2009.

download

Sinotte M, Diorio C, Berube S, Pollak M, Brisson J. Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr 89: 634-40, 2009.

download

Wolpin BM, Meyerhardt JA, Chan AT, Ng K, Chan JA, Wu K, Pollak MN, Giovannucci EL, Fuchs CS. Insulin, the insulin-like growth factor axis, and mortality in patients with nonmetastatic colorectal cancer. J Clin Oncol 27: 176-85, 2009.

download

Okereke OI, Selkoe DJ, Pollak MN, Stampfer MJ, Hu FB, Hankinson SE, Grodstein F. A profile of impaired insulin degradation in relation to late-life cognitive decline: A preliminary investigation. Int J Geriatr Psychiatry 24: 177-82, 2009. 

download

Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M, Dunn SE. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-46, 2008.

download

Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab 22: 625-38, 2008.

download

So AI, Levitt RJ, Eigl B, Fazli L, Muramaki M, Leung S, Cheang MCU, Nielsen TO, Gleave M, Pollak M. Insulin-like growth factor binding protein-2 is a novel therapeutic target associated with breast cancer. Clin Cancer Res 14: 6944-54, 2008.

download

Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. Nat Cancer Rev 8: 915-28, 2008.

download

Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10: R86, 2008.

download

Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 14: 6364-70, 2008.

download

Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schröder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461-71, W83-8, 2008.

download

Stolzenberg-Solomon RZ, Weinstein S, Pollak M, Tao Y, Taylor PR, Virtamo J, Albanes D. Prediagnostic adiponectin concentrations and pancreatic cancer risk in male smokers. Am J Epidemiol 168: 1047-55, 2008.

download

Fuchs CS, Goldberg RM, Sargen DJ, Meyerhardt JA, Wolpin BM, Green EM, Pitot HC, Pollak M. Plasma insulin-like growth factors, insulin-like binding protein-3 and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res 14: 8263-9, 2008.

download

Diorio C, Sinotte M, Brisson J, Berube S, Pollak M. Vitamin d pathway polymorphisms in relation to mammographic breast density. Cancer epidemiol Biomarkers Prev 17: 2505-8, 2008.

download

Zakikhani M, Dowling RJO, Sonenberg N, Pollak MN. Effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res 1: 369-75, 2008.

download

Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen P, Gaziano JM, Pollak M, Stampfer M. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol 9: 1039-47, 2008.

download

Pollak M. Targeting insulin and insulin-like growth factor signalling in oncology. Curr Opin Pharmacol 8: 384-92, 2008.

download

Page JH, Ma J, Pollak M, Manson JE, Hankinson SE. Plasma insulin-like growth factor 1 and binding-protein 3 and risk of myocardial infarction in women: a prospective study. Clin Chem 54: 1682-8, 2008.

download

Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J, Calle EE, Chanock S, Clavel-Chapelon F, Cox DG, Dorronsoro M, Dossu L, Haiman CA, Hankinson SE, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Linseisen J, Lund E, Manjer J, McCarty C, Peeters PH, Pike MC, Pollak M, Riboli E, Stram DO, Tjonneland A, Travis RC, Trichopoulos D, Tumino R, Yeager M, Ziegler RG, Feigelson HS. IGF-1, IGFBP-1, IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS ONE 3: e2578, 2008.

download

Neuhouser ML, Schenk J, Song YJ, Tangen CM, Goodman PJ, Pollak M, Penson DF, Thompson IM, Kristal AR. Insulin-like growth factor-I, insulin-like growth factor binding protein-3 and risk of benign prostate hyperplasia in the prostate cancer prevention trial. Prostate 68: 1477-86, 2008.

download

Max JB, Limburg PJ, Ogunseitan A, Stolzenberg-Solomon RZ, Vierkant RA, Pollak M, Sellers TA, Virtamo J, Cerhan JR, Albanes D. IGF-I, IGFBP-3, and IGF-I/IGFBP-3 Ratio: No Association with Incident Colorectal Cancer in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. Cancer Epidemiol Biomarkers Prev 17: 1832-4, 2008.

download

Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. High insulinlike growth factor binding protein 1 level predicts incident congestive heart failure in the elderly. Am Heart J 155: 1006-12, 2008.

download

Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. Gynecol Oncol 110: 246-50, 2008.

download

Lacy MQ, Alsina M, Fonseca R, Paccagnella ML, Melvin CL, Yin D, Sharma A, Enriquez Sarano M, Pollak M, Jagannath S, Richardson P, Gualberto A. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulin like growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 26: 3196-203, 2008.

download

Diorio C, Brisson J, Berube S, Pollak M. Intact and total insulin-like growth factor-binding protein-3 levels in relation to breast cancer risk factors: a cross-sectional study. Breast Cancer Res 10: R42, 2008.

download

Algire C, Zakikhani M, Blouin MJ, Shuai JH, Pollak M. Metformin attenuates the stimulatory effect of a high energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer 15: 833-9, 2008.

download

Van Oijen M, Okereke OI, Kang JH, Pollak MN, Hu FB, Hankinson SE, Grodstein F. Fasting insulin levels and cognitive decline in older women without diabetes. Neuroepidemiology 30: 174-9, 2008.

download

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Manson JE, Li J, Harris TG, Rohan TE, Xue X, Ho GY, Einstein MH, Kaplan RC, Burk RD, Wylie-Rosett J, Pollak MN, Anderson G, Howard BV, Strickler HD. A prospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarker Prev 17: 921-9, 2008.

download

Diorio C, Brisson J, Berube S, Pollak M. Genetic polymorphisms involved in insulin-like growth factor (IGF-I) pathway in relation to mammographic breast density and IGF levels. Cancer Epidemiol Biomarkers Prev 17: 880-8, 2008.

download

Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco EL; Biomarkers of Cervical Cancer Risk (BCCR) Study Team (Michael Pollak is member). Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia. Int J Cancer 122: 2820-6, 2008.

download

Kasper JS, Liu Y, Pollak MN, Rifai N, Giovannucci E. Hormonal profile of diabetic men and the potential link to prostate cancer. Cancer Causes Control 19: 703-710, 2008.

download

Kaplan RC, McGinn AP, Pollak MN, Kuller L, Strickler HD, Rohan TE, Xue X, Kritchevsky SB, Newman AB, Psaty BM. Total insulin like growth factor 1 and insulin like growth factor binding protein levels, functional status, and mortality in older adults. J Am Geriatr Soc 56: 652-60, 2008.

download

Okereke OI, Pollak MN, HU FB, Hankinson SE, Selkoe DJ, Grodstein F.Plasma C-peptide levels and rates of cognitive decline in older, community-dwelling women without diabetes. Psychoendocrinology 33: 455-461, 2008.

download

Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH, Gallagher RP. Prostate cancer risk in relation to insulin-like growth factor (IGF)-I and IGF-binding protein-3: a prospective multiethnic study. Cancer Epidemiol Biomarkers Prev 17: 252-4, 2008.

download

Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, Kuller L, Xue X, Newman AB, Strotmeyer ES, Psaty BM, Kaplan RC. Insulin-like growth factor axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 18:166-173, 2008.

download

Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R, Klotz LH, Pollak M. Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99: 1793-800, 2007.

download

Singh RP, Deep G, Blouin M-J, Pollak MN, Agarwal R. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft. Carcinogenesis 28: 2567-74, 2007.

download

Schernhammer ES, Tworoger SS, Eliassen AH, MIssmer SA, Holly JM, Pollak MN, Hankinson SE. Body shape throughout life and correlations with IGFs and GH. Endocrine-Related Cancer 14:721-732, 2007.

download

Raina K, Blouin M-J, Singh RP, Majeed N, Deep G, Varghese L, Glodé LM, Greenberg NM, Hwang D, Cohen P, Pollak MN, Agarwal R. Dietary feeding of silibinin inhibits prostate tumor growth and progression in transgenic adenocarcinoma of the mouse prostate model. Cancer Res 67:11083-91, 2007.

download

Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-12, 2007.

download

Borugian MJ, Spinelli JJ, Sun Z, Kolonel LN, Oakley-Girvan I, Pollak M, Whittemore AS, Wu AH, Gallagher RP. Prediagnostic C-peptide and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 2164-5, 2007.

download

Rich-Edwars JW, Ganmaa D, Pollak MN, Nakamoto EK, Kleinman K, Tserendolgor U, Willett WC, Frazier AL. Milk consumption and the prepubertal somatotropic axis. Nutr J 6: 28, 2007. 

download

Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak M, Fuchs CS. Circulating insulin-like growth factor and the risk of pancreatic cancer in four prospective cohorts. Br J Cancer 97: 98-104, 2007.

download

Michaud DS, Wolpin B, Giovannucci E, Liu S, Cochrane B, Manson JE, Pollak M, Ma J, Fuchs CS. Prediagnostic plasma C-Peptide and pancreatic cancer risk in men and women. Cancer Epidemiol Biomarkers Prev 16: 2101-9, 2007.

download

Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, Cochrane BB, Rohan TE, Ma J, Pollak M, Fuchs CS. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res 67: 7923-8, 2007.

download

Li H, Bubley GJ, Balk SP, Gaziano JM, Pollak M, Stampfer MJ. Hypoxia-inducible factor-1 alpha gene polymorphisms, circulating insulin-like growth factor binding protein-3 levels and prostate cancer. Prostate 67: 1354-91, 2007.

download

Tworoger SS, Lee IM, Buring JE, Pollak MN, Hankinson SE. Insulin-like growth factors and ovarian risk: a nested case-control study in three cohorts. Cancer Epidemiol Biomarkers Prev 16: 1691-5, 2007.

download

Pollak MN. Insulin, insulin-like growth factors, insulin resistance, and neoplasia. Am J Clin Nutr 86: 820S-2S, 2007.

download

De Bono JS, Attard G, Adjei A,Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clin Cancer Res 13: 3611-6, 2007.

download

Levitt RJ, Zhao Y, Blouin M-J, Pollak M. The hedgehog pathway inhibitor cyclopamine increase levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Lett 255: 300-6, 2007.

download

Brisson J, Berube S, Diorio C, Sinotte M, Pollak M, Masse B. Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin D. Cancer Epidemiol Biomarkers Prev 16: 929-33, 2007.

download

McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ. C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol 109: 933-41, 2007.

download

Lonn S, Inskip PD, Pollak MN, Weinstein SJ, Virtamo J, Albanes D. Glioma risk in relation to serum levels of insulin-like growth factors. Cancer Epidemiol Biomarkers Prev 16: 844-6, 2007.

download

Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Pollak MN, Franco EL. Insulin-like growth factor-I and risk of high-grade cervical intraepihtelial neolplasia. Cancer Epidemiol Biomarkers Prev 16: 716-22, 2007.

download

Kaplan RC, McGinn AP, Pollak MN, Kuller LH, Strickler HD, Rohan TE, Cappola AR, Xue X, Psaty BM. Association of total IGF-I, IGFBP-1 and IGFBP-3 levels with incident coronary events and ischemic stroke. J Clin Endocrinol Metab 92: 1319-25, 2007.

download

Tamimi RM, Cox DG, Kraft P, Pollak MN, Haiman CA, Cheng I, Freedman ML, Hankinson SE, Hunter DJ, Colditz GA. Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res 9: R18, 2007.

download

Pollak M. Insulin-like growth factor-related signaling and cancer development. Recent Results Cancer Res 174: 49-53, 2007.

download

Eliassen AH, Tworoger SS, Mantzoros CS, Pollak MN, Hankinson SE. Circulating insulin and C-peptide levels and risk of breast cancer among predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev 16: 161-4, 2007.

download

Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and cognitive performance in older women. Neurobiol Aging 28: 135-42, 2007.

download

Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26: 1811-9, 2007.

download

Tran CD, Diorio C, Berube S, Pollak M, Brisson J. Relation of insulin-like growth factor (IGF) I and IGF-binding protein 3 concentrations with intakes of fruit, vegetables, and antioxidants. Am J Clin Nutr 84: 1518-26, 2006

download

Ahn J, Weinstein SJ, Snyder K, Pollak MN, Virtamo J, Albanes D. No association between serum insulin-like growth factor (IGF)-1, IGF-binding protein-3, and lung cancer. Cancer Epidemiol Biomarkers Prev 15: 2010-2, 2006.

download

Gong Z, Neuhouser ML, Goodman PJ, Albanes D, Chi C, Hsing AW, Lippman SM, Platz EA, Pollak MN, Thompson IM, Kristal AR. Obesity, diabetes, and risk of prostate cancer: Results from the prostate cancer prevention trial. Epidemiol Biomarkers Prev 15: 1977-83, 2006.

download

Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Research 66: 10269-73, 2006.

download

Tseng PH, Weng SC, Wang YC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor. Mol Pharmacol 70: 1534-41, 2006.

download

Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-1, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Related Cancer 13: 583-92, 2006.

download

Missmer SA, Spiegelman D, Bertone-Johnson ER, Barbieri RL, Pollak MN, Hankinson SE. Reproducibility of plasma steroid hormones, prolactin, and insulin-like growth factor levels among premenopausal women over a 2-3 year period. Cancer Epidemiol Biomarkers Prev 15: 972-8, 2006.

download

Harris TG, Strickler HD, Yu H, Pollak MN, Monrad ES, Travin MI, Xue X, Rohan TE, Kaplan RC. Specimen processing time and measurement of total insulin-like growth factor-1 (IGF-1), free IGF-1, and IGF binding protein-3 (IGFBP-3). Growth Horm IGF Res 16: 86-92, 2006.

download

Wei EK, Ma J, Pollak MN, Rifai N, Fuchs C, Hankinson SE, Giovannucci E. C-peptide, insulin-like growth factor binding protein-1, glycosylated hemoglobin, and the risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 15: 750-5, 2006.

download

Gotlieb W, Bruchim I, Gu J, Shi Y, Camirand A, Blouin M-J, Zhao Y, Pollak MN. Insulin-like growth factor receptor 1 targeting in epithelial ovarian cancer. Gynecol Oncol 100: 389-96, 2006.

download

Rousseau MC, Parent ME, Pollak MN, Siemiatycki J. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 118: 2105-9, 2006.

download

Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor 1 and the risk of postmenopausal breast cancer. Int J Cancer 118: 1279-84, 2006.

download

Diorio C, Bérubé S, Byrne C, Mâssé B, Hébert-Croteau N, Yaffe M, Côté G, Pollak M, Brisson J. Influence of insulin-like growth factors on the strength of the relation of vitamin D and calcium intakes to mammographic breast density. Cancer Res 66: 588-97, 2006.

download

Diorio C, Pollak M, Byrne C, Mâssé B, Hébert-Croteau N, Yaffe M, Côté G, Bérubé S, Brisson J. Levels of C-peptide and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 2661-4, 2005.

download

Levitt R, Georgescu M, Pollak M. PTEN-induction in U251 glioma cells decreases the expression of insulin-like growth factor binding protein-2. Biochem and Biophys Res Comm 336: 1056-61, 2005.

download

Kucab JE, Lee C, Chen CH, Zhu J, Blake Gilks C, Cheang M, Huntsman D, Yorida E, Emerman J, Pollak M, Dunn S. Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours. Breast Cancer Res 7: R796-R807, 2005.

download

Pinheiro SP, Holmes MD, Pollak MN, Barieri R, Hankinson S. Racial differences in premenopausal endogenous hormones. Cancer Epidemiol Biomarkers Prev 14: 2147-53, 2005.

download

Bérubé S, Diorio C, Mâssé B, Hébert-Croteau N, Byrne C, Côté G, Pollak M, Yaffe M, Brisson J. Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 1553-9, 2005.

download

Majeed N, Blouin MJ, Kaplan-Lefko PJ, Barry-Shaw J, Greenberg NM, Gaudreau P, Bismar TA, Pollak M. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. Oncogene 24: 4736-40, 2005.

download

Camirand A, Zakikhani M, Young F, Pollak MN. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibatory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Research 7: R570-9, 2005.

download

Sutherland BW, Kucab J, Wu J, Lee C, Cheang M, Yorida E, Turbin D, Dedhar S, Nelson C, Pollak M, Leighton Grimes H, Miller K, Badve S, Huntsman D, Blake-Gilks C, Chen M, Pallen CJ, Dunn SE. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24: 4281-92, 2005.

download

Platz EA, Pollak MN, Leitzmann MF, Stampfer MJ, Willett WC, Giovannucci E. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. Cancer Causes and Control 16: 255-62, 2005.

download

Meyerhardt JA, Sloan JA, Sargent DJ, Goldberg RM, Pollak M, Morton RF, Ramanathan RK, Williamson SK, Findlay BP, Fuchs CS. Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer. Cancer Epidemiol Biomarkers Prev 14: 1402-10, 2005.

download

Diorio C, Pollak M, Byrne C, Masse B, Hebert-Croteau N, Yaffe M, Cote G, Berube S, Morin C, Brisson J. Insulin-like growth factor-1, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev 14: 1065-73, 2005.

download

Nam RK, Trachtenberg J, Jewitt MA, Toi A, Evans A, Narod SA, Pollak M. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk. Cancer Epidemiology Biomarkers Prev 14: 1270-3, 2005.

download

Wei EK, Ma J, Pollak MN, Rifai N, Fuchs CS, Hankinson SE, Giovannucci E. A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 14: 850-5 2005.

download

Kristal AR, King IB, Albanes D, Pollak MN, Stanzyk FZ, Santella RM, Hoque A. Centralized blood processing for the selenium and vitamin E cancer prevention triaL: Effects of delayed processing on carotenoids, tocopherols, insulin-like growth factor-I, insulin-like growth factor binding protein 3, steroid hormones, and lymphocyte viability. Cancer Epidemiology Biomarkers Prev 14: 727-730, 2005.

download

Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 3: 699-704, 2005.

download

Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23: 455-60, 2005.

download

Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Solicited Review. Nature Rev Cancer 4: 505-18, 2004.

download

Camirand A, Pollak M. Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells. Br J Cancer 90: 1825-29, 2004.

download

Stolzenberg-Solomon RZ, Limburg P, Pollak M, Taylor PR, Virtamo J, Albanes D. Insulin-like growth factor (IGF)-1, IGF-binding protein-3, and pancreatic cancer in male smokers. Cancer Epidemiol Biomarkers Prev 13: 438-44, 2004.

download

Lai JH, Vesprini D, Zhang W, Yaffe MJ, Pollak M, Narod SA. A polymorphic locus in the promoter region of the IGFBP3 gene is related to mammographic breast density. Cancer Epidemiology Biomarkers Prev 13: 573-82, 2004.

download

Ma J, Giovannucci EL, Pollak MN, Leavitt A, Tao Y, Gaziano J, Stampfer MJ. A prospective study of plasma c-peptide and colorectal cancer risk in men. J Natl Cancer Inst 96: 546-53, 2004.

download

Labrie F, Champagne P, Labrie C, Roy J, Laverdiere J, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L'Esperance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. J Clin Oncol 22: 864-71, 2004.

download

Levitt RJ, Buckley J, Blouin M-J, Schaub B, Triche TJ, Pollak M. Growth inhibiton of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 316: 421-8, 2004.

download

Schairer C, Hill D, Fears T, Ziegler R, Hoover R, Pollak M. Serum concentrations of IGF-I, IGFBP-3, and c-peptide and risk of hyperplasia and cancer of the breast in postmenopausal women. Int J Cancer 108: 773-9, 2004. 

download

Lu Y, Zi X, Zhao Y,Pollak MN. Overexpression of ErbB2 receptor inhibits IGF-1-induced Shc-MAPK signaling pathway in breast cancer cells. Biochem Biophys Res Commun 313:709-15, 2004.

download

Lu Y, Zi X, Pollak MN. Molecular mechanisms underlying IGF-1-induced attenuation of the growth inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer 108: 334-41, 2004.

download

Nam RK, Zhang WW, Trachtenberg J, Jewett MA, Emami M, Vesprinin D, Chu W, Ho M, Sweet J, Toi A, Pollak M, Narod SA. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer. Cancer Epidemiol Biomarkers Prev 12: 1429-37, 2003.

download

Pollak M, Foulkes W. Challenges to cancer control by screening. Nature Reviews Cancer 3: 297-303, 2003.

download

Giovannucci E, Pollak M, Liu Y, Platz EA, Majeed N, Rimm EB, Willet WC. Nutritional predictors of insulin-like growth factor-I and their relationships to cancer in men. Cancer Epidemiology Biomarkers & Prevention 12: 84-89, 2003.

download

Saydah SH, Platz EA, Rifai N, Pollak MN, Brancati FL, Helzlsouer KJ. Association of markers of insulin and glucose control with subsequent colorectal cancer risk. Cancer Epidemiology Biomarkers & Prevention 12: 412-418, 2003.

download

Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN. Polymorphic variation at the -202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. International Journal of Cancer 107: 60-64, 2003.

download

Nomura AM, Stemmermann GN, Lee J,Pollak MN. Serum Insulin-like Growth Factor 1 and Subsequent Risk of Colorectal Cancer among Japanese-American Men. American Journal of Epidemiology 158: 424-431, 2003.

download

Woodson K, Tangrea JA, Pollak M, Copeland TD, Taylor PR, Virtamo J, Albanes D. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Research 63: 3991-4, 2003.

download

Ismail AH,Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG. Serum insulin-like growth factor (IGF) – 1 and IGF-binding protein-3 do not correlate with Gleason score or quantity of prostate cancer in biopsy samples. British Journal of Urology International 92: 699-702, 2003.

download

VanHouten JN, Dann P, Stewart AF, Watson CJ, Karaplis AC,Pollak M, Wysolmerski JJ. Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. The Journal of Clinical Investigation 112: 1429-1436, 2003.

download

Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, Fontana J, Chinni S, Davis J, Forman J, Wood DP, Kucuk O. Soy isoflavones in the treatment of prostate cancer. Nutri Cancer 47: 111-7, 2003.

download

Ismail AH, Pollak M, Behlouli H, Tanguay S, Bégin LR, Aprikian AG. Insulin-like growth factor-1 and insulin-like growth factor binding protein-3 for prostate cancer detection in patients undergoing prostate biopsy. The Journal of Urology 168: 2426-30, 2002.

download

Camirand A, Lu YH, Pollak M. Co-targeting HER2/erbB2 and IGF-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Medical Science Monitor 8: BR521-526, 2002.

download

Levitt RJ, Pollak M. Insulin-like growth factor-I antagonizes the anti-proliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Research 62: 7372-7376, 2002.

download

Kucuk O, Sarkar FH, Djuric Z, Sakr W, Pollak MN, Khachik F, Banerjee M, Bertram JS, Wood DP Jr. Effects of lycopene supplementation in patients with localized prostate cancer. Experimental Biology and Medicine 227: 881-885, 2002.

download

Spitz MR, Barnett MJ, Goodman GE, Thornquist MD, Wu X, Pollak M. Serum Insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: A case-control study nested in the beta-carotene and retinol efficacy trial cohort. Cancer Epidemiology Biomarkers & Prevention 11: 1413-1418, 2002.

download

Giovannucci E, Haiman CA, Platz EA, Hankinson SE, Pollak MN. Dinucleotide repeat in the insulin-like growth factor-I gene is not related to risk of colorectal adenoma. Cancer Epidemiology Biomarkers & Prevention 11: 1509-1510, 2002.

download

Deitel K, Dantzer D, Ferguson P, Pollak M, Beamer W, Andrulis I, Bell R. Reduced growth of human sarcoma xenografts in hosts homozygous for the lit mutation. Journal of Surgical Oncology 81: 75-79, 2002.

download

Holmes MD, Pollak MN, Hankinson SE. Lifestyle correlates of plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiology, Biomarkers & Prevention 11: 862-867, 2002.

download

Holmes MD, Pollak MN, Willett WC, Hankinson SE. Dietary correlates of plasma insulin-like growth factor-I and insulin-like growth factor binding protein-3 concentrations. Cancer Epidemiology, Biomarkers & Prevention 11: 852-861, 2002.

download

Kucuk O, Sarkar FH, Sakr W, Khachik F, Djuric Z, Banerjee M, Pollak MN, Bertram JS, Wood DP. Lycopene in the treatment of prostate cancer. Pure and Applied Chemistry 74: 1443-50, 2002.

download

Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE. A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. International Journal of Cancer 100: 332-6, 2002.

download

Toppmeyer D, Seidman AD, Pollak M, Russell C, Tkaczuk K, Verma S, Overmoyer B, Garg V, Ette E, Harding MW, Demetri GD. Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clinical Cancer Research 8: 670-8, 2002.

download

Giovannucci E, Pollak M. Risk of cancer after growth-hormone treatment. [editorial] Lancet 360: 268-9, 2002.

download

Chan JM, Stampfer MJ, Ma J, Gann P, Gaziano JM, Pollak M, Giovannucci E. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. Journal of the National Cancer Institute 94: 1099-1106, 2002.

download

Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). Journal of the National Cancer Institute 93: 1852-1857, 2001. 

[see also favourable editorial comment [.pdf] - J Natl Cancer Inst 93: 1830-2, 2001]

download

Ma J, Giovannucci E, Pollak M, Chan JM, Gaziano JM, Willett W, Stampfer MJ. Milk intake, circulating levels of insulin like growth factor-I and risk of colorectal cancer in men. Journal of the National Cancer Institute 93: 1330-1336, 2001.

download

Chan TW, Pollak M, Huynh H. Inhibition of insulin-like growth factor signaling pathways in mammary gland by pure antiestrogen ICI 182,780. Clinical Cancer Research 7: 2545-2554, 2001.

download

Kucuk O, Sarkar FH, Sakr W, Djuric Z, Pollak M N, Khachik Y, Banerjee M, Grignon D, Bertram JS, Crissman JD, Pontes EJ, Wood DP Jr. Phase II randomized clinical trial of lycopene supplementation before radical prostatectomy. Cancer Epidemiology Biomarkers & Prevention 10: 861-8, 2001.

download

Thorner M and writing committee (including Pollak M). Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the growth hormone research society. Journal of Clinical Endocrinology & Metabolism 86:1868-1870, 2001.

download

Nickerson T, Chang F, Tran C, Lorimer D, Smeekens SP, Sawyers CI, Pollak M. In vivo of LAPC-9 and LNCaP cancer models to androgen independence is associated with increased expression of IGF-I and IGF-IR. Cancer Research 61: 6276-6280, 2001.

download

He B, Deckelbaum RA, Miao D, Lipman ML, Pollak M, Goltzman D, Karaplis AC. Tissue-Specific targeting of the Pthrp gene: The generation of mice with floxed alleles. Endocrinology 142: 2070-7, 2001.

download

Chokkalingam AP, Pollak M, Fillmore C, Gao Y, Stanczyk FZ, Deng J, Sesterhenn IA, Mostofi FK, Fears TR, Madigan MP, Ziegler RG, Fraumeni JF Jr, Hsing AW. Insulin-like growth factors and prostate cancer: a population-based cased-control study in China. Cancer Epidemiology Biomarkers & Prevention 10:421-7, 2001.

download

Pollak M, Blouin M-J, Jian-Chun Z, Kopchick JJ. Reduced mammary gland carcinogenesis in transgenic mice expressing a growth hormone antagonist. British Journal of Cancer 85: 428-430, 2001.

download

Tolcher AW, Kennedy A, Padley RJ, Majeed N, Pollak M, Kantoff PW. Other novel agents: Rationale and current status as chemopreventive agents. Urology 57: 86-9, 2001.

download

Chokkalingam AP, McGlynn KA, Gao Y, Pollak M, Deng J, Sesterhenn IA, Mostofi FK, Fraumeni JF Jr, Hsing AW. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Research 61: 4333-6, 2001.

download

Pollak M. Insulin-like growth factors (IGFs) and prostate cancer. Epidemiologic Reviews 23: 59-66, 2001.

download

Trojan D, Collet J, Pollak M, Shapiro S, Jubelt B, Miller R, Agre J, Munsat TL, Hollander D, Tandan R, Robinson A, Finch L, Ducruet T, Cashman N. Serum insulin-like growth factor-I (IGF-I) does not correlate positively with isometric strength, fatigue, and quality of life in post-polio syndrome. Journal of the Neurological Sciences 182:107-115, 2001.

download

Jernström H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, and Narod SA. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for pre-menopausal breast cancer risk. Molecular Genetics and Metabolism 72: 144-54, 2001.

download

Deal C, Ma J, Wilkin F, Paquette J, Rozen F, Ge B, Hudson T, Stampfer M, Pollak M. Novel promoter polymorphism in IGFBP3: Correlation with serum levels and interaction with known regulators. Journal of Clinical Endocrinology & Metabolism 86: 1274-80, 2001.

download

Jernström H, Wilkin F, Deal C, Chu W, Tao Y, Majeed N, Narod S, Hudson T,Pollak M. Genetic and non-genetic factors associated with variation of plasma levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in healthy premenopausal women. Cancer Epidemiology Biomarkers & Prevention 10: 377-384, 2001.

download

Nabholtz J, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, Von Euler M. Anastrazole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. J Clin Oncol 18: 3758-67, 2000.

download

Pollak M. The question of a link between insulin-like growth factor physiology and neoplasia. Growth Hormone IGF Res 10 Suppl B: 21-4, 2000.

download

Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 60: 5617-20, 2000.

download

Byrne C, Colditz G, Willett W, Speizer F, Pollak M, Hankinson S. Plasma Insulin-like Growth Factor (IGF) I, IGF-binding Protein 3, and mammographic Density. Cancer Res 60: 3744-8, 2000.

download

Wilkin F, Paquette J, Ledru E, Mamelin C, Pollak M, Deal C. H19 sense and antisense transgenes modify insulin-like growth factor-II mRNA levels. Eur J Biochem 267: 4020-7, 2000.

download

Platz EA, Pollak MN, Willett W, Giovannucci E. Vertex balding, plasma insulin-like growth factor 1, and insulin-like growth factor binding protein 3. J Am Acad Dermatol 42: 1003-7, 2000.

download

Pollak M. Insulin-like growth factor physiology and cancer risk. Eur J Cancer 36: 1224-8, 2000. 

download

Giovannucci E, Pollak M, Platz E, Willett W, Stampfer M, Majeed N, Colditz G, Speizer F, Hankinson S. A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 9: 345-9, 2000.

download

Foulkes WD, Chappuis PO, Wong N, Brunet J, Vesprini D, Rozen F, Yuan ZQ, Pollak MN, Kuperstein G, Narod SA, Bégin LR. Primary node negative breast cancer in BRCA1 mutation carriers has a poor outcome. Ann Oncol 3: 307-13, 2000.

download

Miyake H, Pollak M, Gleave M. Castration-induced upregulation of IGFBP-5 potentiates IGF-I activity and accelerates progression to androgen-independence in prostate cancer models. Cancer Res 60: 3058-64, 2000.

download

Huynh H, Beamer W, Pollak M, Chan T. Modulation of transforming growth factor beta 1 gene expression in the mammary gland by insulin-like growth factor I and octreotide. Int J Oncol 16: 277-81, 2000.

download

Platz E, Pollak M, Rimm E, Majeed N, Tao Y, Willett W, Giovannucci E. Racial variation in insulin-like growth factor-1 and binding protein-3 concentrations in middle-aged men. Cancer Epidemiol Biomarkers Prev 8: 1107-10, 1999.

download

Nickerson T, Pollak M. Bicalutamide (Casodex)-induced prostate regression involves increased gene expression of insulin-like growth factor binding proteins. Urology 54: 1120-5, 1999.

download

Buhlmann C, Borchers T, Pollak M, and Spener F. Fatty acid metabolism in human breast cancer cells (MCF7) transfected with heart-type fatty acid binding protein. Mol Cell Biochem 199: 41-8, 1999.

download

Rozen F, Pollak M. Inhibition of insulin-like growth factor I receptor signaling by the vitamin D analogue EB1089 in MCF-7 breast cancer cells: A role for insulin-like growth factor binding proteins. Int J Oncol. 15: 589-94, 1999.

download

Nickerson T, Miyake H, Gleave M, and Pollak M Castration-induced apoptosis of androgen-dependent Shinogi carcinoma is associated with increased expression of genes encoding IGF-binding proteins. Cancer Res 59: 3392-5, 1999.

download

Nickerson T, Zhang J, Pollak M. Regression of DMBA-induced breast carcinoma following ovariectomy is associated with increased expression of genes encoding insulin-like growth factor binding proteins. Int J Oncol 14: 987-90, 1999.

download

Rosen C and Pollak M. Circulating IGF-I: a new perspective for a new century. Trends Endocrinol Metab 10: 136-41, 1999.

download

Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Rev 17: 383-90, 1998-1999.

download

Pollak M, Beamer W, Zhang J. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 17: 383-90, 1999.

download

Ma J, Pollak M, Giovannucci E, Chan J, Tao Y, Hennekens C, Stampfer M. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein 3. J Natl Cancer Inst 91: 620-5, 1999

[see also favorable editorial comment [.pdf] - J Natl Cancer Inst 91: 579-581, 1999]

download

Ingle J, Suman V, Kardinal C, Krook J, Mailliard J, Veeder M, Loprinzi C, Dalton R, Hartmann L, Conover C, Pollak M. A randomized trial of tamoxifen alone or combined with octreotide in the treatment of women with metastatic breast carcinoma. Cancer 85: 1284-92, 1999.

download

Burrow S, Andrulis I, Pollak M, Bell R. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol 69: 21-7, 1998.

download

Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 13: 865-9, 1998.

download

Huynh H, Pollak M, Zhang J. Regulation of IGF-II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB 1089. Int J Oncol 13: 137-143, 1998.

download

Pollak M. Effects of anti-estrogens on insulin-like growth factor-I physiology systemically and in the uterus. Eur J Cancer 34 (Supp 4) S1-S8, 1998.

download

Hankinson S, Willett W, Colditz G, Hunter D, Michaud D, Deroo B, Rosner B, Speizer F, Pollak M. Circulating concentrations of insulin-like growth factor I and risk of breast cancer. Lancet 351: 1393-96, 1998.

[see also favorable editorial comment [.pdf] : Lancet 351: 1373-4, 1998]

download

Pollak M. Endocrine effects of IGF-I on normal and transformed breast epithelial cells: potential relevance to strategies for breast cancer treatment and prevention. Breast Cancer Res Treat 47: 209-17, 1998.

download

Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens C, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-566, 1998

[see also favorable editorial comment [.pdf] - Science 279: 475, 1998]

download

Pollak M, Schally A. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc for Exp Biol Med 217: 143-52, 1998.

download

Nickerson T, Pollak M,Huynh H. Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding IGF binding proteins 2,3,4, and 5. Endocrinology 139: 807-810, 1998.

download

Pollak M. The potential role of somatostatin analogues in breast cancer treatment. Yale J Biol Med 70: 535-9, 1997.

download

Huynh H, Beamer W, Pollak M. Overexpression of IGFBP-4 by MCF-7 breast cancer cells is associated with reduced responsiveness to IGFs in vitro and reduced tumor growth in vivo. Int J Oncol 11: 193-7, 1997.

download

Foulkes W, Wong N, Brunet J, Begin L, Zhang J, Martinez J, Rozen F, Tonin P, Narod S, Karp S, Pollak M. Germ line BRCA1 mutation is an adverse prognostic factor in Ashkenazi Jewish women with breast cancer. Clin Cancer Res 3: 2465-9, 1997.

download

Huynh H, Pollak M. Stabilization of mammary-derived growth inhibitor messenger RNA by antiestrogens. Clin Cancer Res 3: 2151-6, 1997.

download

Nickerson T, Huynh H, Pollak M. Insulin-like growth factor binding protein-3 induces apoptosis in MCF7 breast cancer cells. Biochem Biophys Res Commun 237: 690-93, 1997.

download

Karp S, Tonin P, Begin L, Martinez J, Zhang J, Pollak M, Foulkes W. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi Jewish women. Cancer 80: 435-41, 1997.

download

Rozen F, Yang X, Huynh H, Pollak M. Antiproliferative action of vitamin-D-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst 89: 652-6, 1997.

download

Huynh H, Nickerson T, Pollak M, Yang X. Regulation of IGF-I receptor expression by the pure antiestrogen ICI 182780. Clin Cancer Res 2: 2037-42, 1996.

download

Huynh H, Yang YX, Pollak M. A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Diff 7: 1501-6, 1996.

download

Huynh H, Alpert L, Pollak M. Pregnancy - dependent growth of mammary tumors is associated with overexpression of insulin-like growth factor II. Cancer Res 56: 3651-4, 1996.

download

Pollak M. Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues. Digestion 57: 29-33, 1996.

download

Pollak M. Peptide growth factors and breast cancer treatment: recent translational research. Recent Results Cancer Res 40: 43-9, 1996.

download

Huynh H , Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016-21, 1996.

download

Huynh H, Alpert L, Pollak M. Silencing of the mammary derived growth inhibitor (MDGI) gene in breast neoplasms is associated with epigenetic changes. Cancer Res 56: 4865-70, 1996.

download

Phelan C, Larsson C, Baird S, Futreal A, Ruttledge M, Morgan K, Tonin P, Huynh H, Korneluk R, Pollak M, Narod S. The human mammary-derived growth inhibitor (MDGI) gene: genomic structure and mutation analysis in human breast tumors. Genomics 34: 63-68, 1996. [Dr. Pollak and Dr. Narod are co-senior authors who contributed equally to this work]

download

Yang XF, Beamer WG, Huynh H, Pollak M. Reduced growth of human breast cancer xenografts in hosts homozygous for the 'lit' mutation. Cancer Res 56: 1509-11, 1996.

download

Huynh H, Pollak M. Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation. Prog Growth Factor Res 6: 495-501, 1995.

download

Montaner J, Harris A, Amar J, Fanning M, and multicenter study group, (including Pollak M.). Octreotide therapy in AIDS-related refractory diarrhea: results of a multicenter Canadian-European study. AIDS 9: 209-10, 1995.

download

Huynh H, Larsson C, Narod S, Pollak M. Tumor suppressor activity of the gene encoding mammary-derived growth inhibitor. Cancer Res 55: 2225-31, 1995.

download

Bloom C, Lisbona A, Bégin LR, Pollak M. Extraosseous Ewing's Sarcoma. Can Assoc Radiol J 46: 131-3, 1995.

download

Sekyi-Otu A, Bell RS, Ohashi C, Pollak M, Andrulis IL. Insulin-like growth factor I (IGF-I) receptors, IGF-I, and IGF-II are expressed in primary human sarcomas. Cancer Res 55: 129-34, 1995.

download

Rosenberg L, Barkun A, Denis M, Pollak M. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75: 23-8, 1995.

download

Huynh H, Pollak M. HH2A, an immortalized bovine breast epithelial cell line that expresses the gene encoding mammary-derived growth inhibitor. In Vitro Cell Dev Biol Anim 31: 25-9, 1995.

download

Weckbecker G, Tolcsvai L, Stolz B, Pollak M, Bruns C. Somatostatin analogue octreotide enhances the antineoplastic effects of tamoxifen and ovariectomy on 7,12-Dimethylbenz (alpha) anthracene-induced rat mammary carcinomas. Cancer Res 54: 6334-7, 1994. [A footnote identifies Dr. Pollak and Dr. Bruns as co-senior authors who contributed equally to this work.]

download

Huynh H, Pollak M. Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophys Res Commun 203: 253-9, 1994.

download

Huynh H, Pollak M. Uterotrophic actions of estradiol and tamoxifen are associated with inhibition of uterine insulin-like growth factor binding protein 3 gene expression. Cancer Res 54: 3115-9, 1994.

download

Sekyi-Otu A, Bell R, Andrulis I, Pollak M. Metastatic behavior of the RIF-1 murine fibrosarcoma: inhibited by hypophysectomy and partially restored by growth hormone replacement. J Natl Cancer Inst 86: 628-32, 1994.

download

Pratt S, Pollak M. Insulin-like growth factor binding protein 3 (IGF-BP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 198: 292-7, 1994.

download

Huynh H, Pollak M. Insulin-like growth factor I gene expression in the uterus is stimulated by tamoxifen and inhibited by the pure antiestrogen ICI 182780. Cancer Res 53: 5585-8, 1993.

download

Tonin P, Ehrenborg W, Lenoir G, Feunteun J, Lynch H, Morgan K, Zazzi H, Vivier A, Pollak M, Huynh H, et al. The human insulin-like growth factor- binding protein 4 gene maps to chromosome region 17q12-21.1 and is close to the gene for hereditary breast-ovarian cancer. Genomics 18: 414-7, 1993.

download

Pollack R, Pollak M, Rochon L. Pregnancy complicated by medulloblastoma with metastases to the placenta. Obstet Gynecol 81: 858-9, 1993.

download

Pratt S, and Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53: 5193-8, 1993.

download

Huynh H, Tetenes E, Wallace L, Pollak M. In vivo inhibition of insulin-like growth factor 1 gene expression by tamoxifen. Cancer Res 53: 1727-30, 1993.

download

Friedel A, Jordan V, Pollak M. Suppression of serum insulin-like growth factor-I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 29a: 1368-72, 1993.

download

Pollak M, Galant K, Poisson R, Harris A. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial. Metabolism 41: 9 Suppl 2, 119-120, 1992.

download

Pollak MN, Huynh H, Lefebvre S. Tamoxifen reduces serum-like growth factor I (IGF-I). Breast Cancer Res Treat 22: 91-100, 1992.

download

Pollak M, Sem A, Richard M, Tetenes E, Bell R. Inhibition of metastatic behavior of murine osteosarcoma by hypophysectomy. J Natl Cancer Inst 84: 966-71, 1992.

download

Tannenbaum G, Gurd W, Lapointe M, Pollak M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology 130: 3395-401, 1992.

download

Malaab S, Pollak MN, Goodyer CG. Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 28A: 788-93, 1992.

download

Yao XJ, Wainberg MA, Pollak M. The inhibitory effects of suramin on HIV-1 are attenuated in the presence of albumin. AIDS 5: 1389-91, 1991.

download

Yao XJ, Wainberg MA, Richard M, Pollak M. The ability of suramin to block CD4-gp120 binding is reduced in the presence of albumin. Antimicrobial agents and chemotherapy 35: 2636-8, 1991.

download

Pollak M, Gora P, Boyarsky A. A mathematical model describing consequences of abnormally high levels of epidermal growth factor receptor on the proliferation of neoplastic cells. Cancer Invest 9: 513-20, 1991.

download

Dawson N, Costanza M, Korzun A, Clamon G, Pollak M, Vogelzong N, Carey R, Norton L. Trimetrexate in untreated and previously treated patients with metastatic breast cancer: a Cancer and Leukemia Group B study. Med and Pediatr Oncol 19: 283-288, 1991.

download

Pollak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 82: 1693-7, 1990.

[see also favorable editorial comment [.pdf] - J Natl Cancer Inst 82: 1662-1663, 1990]

download

Panasci L, Shenouda G, Begin L, Pollak M, Reinke A, Margolese R. Mitomycin C and mitoxantrone chemotherapy for advanced breast cancer: efficacy with minimal gastrointestinal toxicity and alopecia. Cancer Chemother Pharmacol 26: 457-60, 1990.

download

Pollak M, Polychronakos C, Richard M. Insulin-like growth factor 1: a potent mitogen for human osteogenic sarcoma. J Natl Cancer Inst 82: 301-5, 1990.

download

Pollak M, Richard M. Suramin blockade of insulin-like growth factor I- stimulated proliferation of human osteosarcoma cells. J Natl Cancer Inst 82: 1349-52, 1990.

download

Suissa S, Pollak M, Spitzer W, Margolese R. Body size and breast cancer prognosis: a statistical explanation of the discrepancies. Cancer Research 49: 3113-6, 1989.

download

Pollak M, Polychronakos C, Guyda H. Somatostatin analogue SMS 201-995 reduces serum IGF-1 levels in patients with neoplasms potentially dependent on IGF-1. Anticancer Research 9: 889-891, 1989.

download

Pollak M, Polychronakos C, Yousefi S, Richard M. Characterization of insulin-like growth factor I (IGF-I) receptors of human breast cancer cells. Biochem Biophys Res Commun 154: 326-31, 1988.

download

Gonzalez-Vela JL, Panasci L, Black M, Pollak M, Margolese R. Combination chemotherapy with carboplatinum and bleomycin for advanced and recurrent head and neck cancer. A phase II study. J. Surgical Oncology 39: 215-6, 1988.

download

Filmus J, Trent JM, Pollak MN, Buick RN. Epidermal growth factor receptor gene-amplified MDA-468 breast cancer cell line and its nonamplified variants. Mol and Cell Biol 7: 251-257, 1987.

download

Pollak M, Perdue J, Margolese R, Baer K, Richard M. Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Letters 38: 223-230, 1987.

download

Filmus J, Pollak MN, Cailleau R, Buick RN. MDA-468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 128: 898-905, 1985.

download

Filmus J, Pollak MN, Cairncross J, Buick RN. Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. Biochem Biophys Res Commun 131: 207-215, 1985.

download

Buick RN, and Pollak MN. Perspectives on clonogenic tumor cells, stem cells, and oncogenes. Cancer Research 44: 4909-18, 1984.

download

Pollak M. Computer-aided information management systems in clinical trials: a physician's perspective. Computer Prog Biomed 16: 243-52, 1983.

download

Fletcher S, Ratzer G, Pollak M. Computer-based appointment scheduling for ambulatory patients. Meth Information Med 17: 167-72, 1978.

download